Document:

Exhibit 10.1

 

COMMON STOCK PURCHASE AGREEMENT

 

This COMMON STOCK PURCHASE AGREEMENT is
made and entered into as of February 14, 2022 (this “Agreement”), by and between CF Principal Investments LLC,
a Delaware limited liability company (the “Investor”), and Wejo Group Limited, an exempted company limited by
shares incorporated under the laws of Bermuda (the “Company”).

 

RECITALS 

 

WHEREAS, the parties desire that, upon the
terms and subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investor, from time to time
as provided herein, and the Investor shall purchase from the Company, up to the lesser of (i) $100,000,000 in aggregate gross purchase
price of newly issued common shares, par value $0.001 per share, in the capital of the Company (the “Common Stock”),
and (ii) the Exchange Cap (to the extent applicable under Section 3.3);

 

WHEREAS, such sales of Common Stock by the
Company to the Investor will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act (“Section 4(a)(2)”)
and/or Rule 506(b) of Regulation D promulgated by the Commission under the Securities Act (“Regulation D”),
and upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all
of the issuances and sales of Common Stock by the Company to the Investor to be made hereunder;

 

WHEREAS, the parties hereto are concurrently
entering into a Registration Rights Agreement in the form attached as Exhibit A hereto (the “Registration Rights Agreement”),
pursuant to which the Company shall register the resale of the Registrable Securities (as defined in the Registration Rights Agreement),
upon the terms and subject to the conditions set forth therein; and

 

WHEREAS, in consideration for the Investor’s
execution and delivery of this Agreement, the Company is concurrently causing its transfer agent to issue to the Investor the Commitment
Shares, pursuant to and in accordance with Section 10.1(ii);

 

NOW, THEREFORE, the parties hereto, intending
to be legally bound, hereby agree as follows:

 

ARTICLE I 

DEFINITIONS 

 

Capitalized terms used in this Agreement shall have the meanings ascribed
to such terms in Annex I hereto, and hereby made a part hereof, or as otherwise set forth in this Agreement.

 

     

     

    

 

ARTICLE II

PURCHASE AND SALE OF COMMON STOCK 

 

Section 2.1. Purchase and Sale of Stock.
Upon the terms and subject to the conditions of this Agreement, during the Investment Period, the Company, in its sole discretion, shall
have the right, but not the obligation, to issue and sell to the Investor, and the Investor shall purchase from the Company, up to the
lesser of (i) $100,000,000 (the “Total Commitment”) in aggregate gross purchase price of duly authorized, validly
issued, fully paid and non-assessable shares of Common Stock and (ii) the Exchange Cap, to the extent applicable under Section 3.3 (such
lesser amount of shares of Common Stock, the “Aggregate Limit”), by the delivery to the Investor of VWAP Purchase
Notices as provided in Article III.

 

Section 2.2. Closing Date; Settlement Dates.
This Agreement shall become effective and binding (the “Closing”) upon (a) the delivery of counterpart signature
pages of this Agreement and the Registration Rights Agreement executed by each of the parties hereto and thereto, and (b) the delivery
of all other documents, instruments and writings required to be delivered at the Closing, in each case as provided in Section 7.1, to
the offices of King & Spalding LLP at 1185 6th Avenue, Floor 34, New York, New York 10036, at 7:30 a.m., New York City
time, on the Closing Date. In consideration of and in express reliance upon the representations, warranties and covenants contained in,
and upon the terms and subject to the conditions of, this Agreement, during the Investment Period, the Company, at its sole option and
discretion, may issue and sell to the Investor, and, if the Company elects to so issue and sell, the Investor shall purchase from the
Company, the Shares in respect of each VWAP Purchase. The delivery of Shares in respect of each VWAP Purchase, and the payment for such
Shares, shall occur in accordance with Section 3.2, provided that all of the conditions precedent in Article VII shall have been
fulfilled at the applicable times set forth in Article VII.

 

Section 2.3. Initial Public
Announcements and Required Filings. The Company shall, not later than 5:00 p.m., New York City time, on the next business
day following the date of this Agreement, file with the Commission a Current Report on Form 8-K disclosing the execution of this
Agreement and the Registration Rights Agreement by the Company and the Investor and describing the material terms thereof,
including, without limitation, the issuance of the Commitment Shares to the Investor in accordance with Section 10.1(ii), and
attaching as exhibits thereto copies of each of this Agreement and the Registration Rights Agreement and if applicable, any press
release issued by the Company disclosing the execution of this Agreement and the Registration Rights Agreement by the Company
(including all exhibits thereto, the “Current Report”). The Company shall provide the Investor and its
legal counsel a reasonable opportunity to comment on a draft of the Current Report prior to filing the Current Report with the
Commission and shall give due consideration to all such comments. From and after the filing of the Current Report with the
Commission, the Company shall have publicly disclosed all material, nonpublic information delivered to the Investor (or the
Investor’s representatives or agents) by the Company or any of its Subsidiaries, or any of their respective officers,
directors, employees, agents or representatives (if any) in connection with the transactions contemplated by the Transaction
Documents. The Company shall use its commercially reasonable efforts to prepare and, as soon as practicable, file with the
Commission the Initial Registration Statement and any New Registration Statement covering only the resale by the Investor of the
Registrable Securities in accordance with the Securities Act and the Registration Rights Agreement. At or before 8:30 a.m. (New York
City time) on the second (2nd) Trading Day immediately following the Effective Date of the Initial Registration Statement and any
New Registration Statement (or any post-effective amendment thereto), the Company shall use its commercially reasonable efforts to
file with the Commission in accordance with Rule 424(b) under the Securities Act the final Prospectus to be used in connection with
sales pursuant to such Registration Statement (or post-effective amendment thereto).

 

    2 

     

    

 

ARTICLE III 

PURCHASE TERMS 

 

Subject to the satisfaction of the conditions set forth in Article
VII, the parties agree as follows:

 

Section 3.1. VWAP Purchases.
Upon the initial satisfaction of all of the conditions set forth in Section 7.2 (the “Commencement” and
the date of initial satisfaction of all of such conditions, the “Commencement Date”) and from time to time
thereafter, subject to the satisfaction of all of the conditions set forth in Section 7.3, the Company shall have the right, but not
the obligation, to direct the Investor, by its timely delivery to the Investor of a VWAP Purchase Notice, in substantially the form
attached hereto as Exhibit D, after 6:00 a.m., New York City time, but prior to 9:00 a.m., New York City time, on a VWAP
Purchase Date, to purchase the applicable VWAP Purchase Share Amount, not to exceed the applicable VWAP Purchase Maximum Amount, at
the applicable VWAP Purchase Price therefor on such VWAP Purchase Date in accordance with this Agreement (each such purchase, a
 “VWAP Purchase”). In addition, the Investor may, in its sole discretion, accept a VWAP Purchase Notice
after 9:00 a.m., New York City time, on a VWAP Purchase Date, provided that such acceptance, once provided, shall be irrevocable and
binding and the Company’s obligation to deliver the shares that are the subject of such VWAP Purchase Notice shall be binding.
The Company may timely deliver a VWAP Purchase Notice to the Investor as often as every Trading Day, so long as all Shares subject
to all prior VWAP Purchases theretofore required to have been received by the Investor as DWAC Shares under this Agreement have been
delivered to the Investor as DWAC Shares in accordance with this Agreement. The Investor is obligated to accept each VWAP Purchase
Notice prepared and delivered by the Company in accordance with the terms of and subject to the satisfaction of the conditions
contained in this Agreement. If the Company delivers any VWAP Purchase Notice directing the Investor to purchase a VWAP Purchase
Share Amount in excess of the applicable VWAP Purchase Maximum Amount, such VWAP Purchase Notice shall be void ab initio to
the extent of the amount by which the VWAP Purchase Share Amount set forth in such VWAP Purchase Notice exceeds such applicable VWAP
Purchase Maximum Amount, and the Investor shall have no obligation to purchase such excess Shares in respect of such VWAP Purchase
Notice; provided, however, that the Investor shall remain obligated to purchase the applicable VWAP Purchase Maximum
Amount in such VWAP Purchase. Notwithstanding anything in this paragraph to the contrary, in the case where the Sale Price falls
below the Threshold Price during a Trading Day, the VWAP Purchase Amount shall be calculated using (i) the VWAP Purchase Share
Percentage of the aggregate shares traded on the Principal Market for such portion of the VWAP Purchase Date the Sale Price is not
below the Threshold Price and (ii) a VWAP Purchase Price calculated using the volume weighted average price of Common Stock sold
during such portion of the VWAP Purchase Date the Sale Price is not below the Threshold Price. Each VWAP Purchase Notice must be
include a VWAP Purchase Share Estimate. Each VWAP Purchase Notice must be accompanied by instructions to the Company’s
Transfer Agent to immediately issue to the Investor an amount of Common Stock equal to the VWAP Purchase Share Estimate, a good
faith estimate by the Company of the number of Shares constituting the applicable VWAP Purchase Share Amount that the Buyer shall
have the obligation to buy pursuant to the VWAP Purchase Notice. In no event shall the Investor, pursuant to any VWAP Purchase,
purchase a number of Shares constituting the applicable VWAP Purchase Share Amount that exceeds the VWAP Purchase Share Estimate
issued on the VWAP Purchase Date in connection with such VWAP Purchase Notice; however, the Investor will immediately return to the
Company any amount of Common Stock issued pursuant to the VWAP Purchase Share Estimate that exceeds the number of Shares
constituting the applicable VWAP Purchase Share Amount the Investor actually purchases in connection with such VWAP Purchase. In no
event shall the Investor, pursuant to any VWAP Purchase, purchase a number of Shares that exceeds the VWAP Purchase Share Estimate
issued on the VWAP Purchase Date in connection with such VWAP Purchase Notice. At or prior to 5:30 p.m., New York City time, on the
VWAP Purchase Date for each VWAP Purchase, the Investor shall provide to the Company a written confirmation for such VWAP Purchase
(each, a “VWAP Purchase Confirmation”) setting forth the applicable VWAP Purchase Price per Share to be
paid by the Investor in such VWAP Purchase, and the total aggregate VWAP Purchase Price to be paid by the Investor for the total
VWAP Purchase Share Amount purchased by the Investor in such VWAP Purchase. Notwithstanding the foregoing, the Company shall not
deliver any VWAP Purchase Notices to the Investor during the Post-Effective Amendment Period.

 

Section 3.2. Settlement. The
Shares constituting the applicable VWAP Purchase Share Amount purchased by the Investor in each VWAP Purchase shall be delivered to
the Investor as DWAC Shares not later than 1:00 p.m., New York City time, on the Trading Day immediately following the applicable
VWAP Purchase Date for such VWAP Purchase (the “VWAP Purchase Share Delivery Date”) (it being acknowledged
and agreed that the Company may not deliver any additional VWAP Purchase Notice to the Investor until all such Shares subject to
such VWAP Purchase, and all Shares subject to all prior VWAP Purchase Notices, have been received by the Investor as DWAC Shares in
accordance with this Agreement). For each VWAP Purchase, the Investor shall pay to the Company an amount in cash equal to the
product of (a) the total number of Shares purchased by the Investor in such VWAP Purchase and (b) the applicable VWAP Purchase Price
for such Shares (the “VWAP Purchase Amount”), as full payment for such Shares purchased by the Investor in
such VWAP Purchase, via wire transfer of immediately available funds, not later than 5:00 p.m., New York City time, on the Trading
Day immediately following the applicable VWAP Purchase Share Delivery Date for such VWAP Purchase, provided the Investor shall have
timely received, as DWAC Shares, all of such Shares purchased by the Investor in such VWAP Purchase on such VWAP Purchase Share
Delivery Date in accordance with the first sentence of this Section 3.2, or, if any of such Shares are received by the Investor
after 1:00 p.m., New York City time, then the Company’s receipt of such funds in its designated account may occur on the
Trading Day next following the Trading Day on which the Investor shall have received all of such Shares as DWAC Shares, but not
later than 5:00 p.m., New York City time, on such next Trading Day. If the Investor fails to pay the VWAP Purchase Amount when due,
the Investor will return the DWAC Shares to the Company. If the Company or the Transfer Agent shall fail for any reason to deliver
to the Investor, as DWAC Shares, any Shares purchased by the Investor in a VWAP Purchase prior to 10:30 a.m., New York City time, on
the Trading Day immediately following the applicable VWAP Purchase Share Delivery Date for such VWAP Purchase, and if on or after
such Trading Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Investor of such Shares that the Investor anticipated receiving from the Company on such VWAP Purchase
Share Delivery Date in respect of such VWAP Purchase, then the Company shall, within one (1) Trading Day after the Investor’s
request, either (i) pay cash to the Investor in an amount equal to the Investor’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased (the “Cover Price”), at which point the
Company’s obligation to deliver such Shares as DWAC Shares shall terminate, or (ii) promptly honor its obligation to deliver
to the Investor such Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price
over the total purchase price paid by the Investor pursuant to this Agreement for all of the Shares purchased by the Investor in
such VWAP Purchase. The Company shall not issue any fraction of a share of Common Stock to the Investor in connection with any VWAP
Purchase effected pursuant to this Agreement. If the issuance would result in the issuance of a fraction of a share of Common Stock,
the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share. All payments to be made by
the Investor pursuant to this Agreement shall be made by wire transfer of immediately available funds to such account as the Company
may from time to time designate by written notice to the Investor in accordance with the provisions of this Agreement.

 

    3 

     

    

 

Section 3.3. Compliance with Rules of Principal
Market.

 

(a) Exchange Cap. The
Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and the Investor shall not purchase or
acquire any shares of Common Stock pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number
of shares of Common Stock that would be issued pursuant to this Agreement and the transactions contemplated hereby would exceed
18,780,646 shares of Common Stock (representing 19.99% of the voting power or number of shares of Common Stock issued and
outstanding immediately prior to the execution of this Agreement), which number of shares shall be reduced, on a share-for-share
basis, by the number of shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be
aggregated with the transactions contemplated by this Agreement under applicable rules of the Principal Market (such maximum number
of shares, the “Exchange Cap”), unless the Company’s stockholders have approved the issuance of
Common Stock pursuant to this Agreement in excess of the Exchange Cap in accordance with the applicable rules of the Principal
Market. For the avoidance of doubt, the Company may, but shall be under no obligation to, request its stockholders to approve the
issuance of Common Stock pursuant to this Agreement; provided, that if such stockholder approval is not obtained, the
Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the
term of this Agreement (except as set forth in Section 3.3(b)).

 

(b) At Market Transaction.
Notwithstanding Section 3.3(a) above, the Exchange Cap shall not be applicable for any purpose of this Agreement and the
transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed the
Base Price (it being hereby acknowledged and agreed that the Exchange Cap shall be applicable for all purposes of this Agreement and
the transactions contemplated hereby at all other times during the term of this Agreement, unless the stockholder approval referred
to in Section 3.3(a) is obtained). The parties acknowledge and agree that the Minimum Price used to determine the Base Price
hereunder represents the lower of (i) the Nasdaq official closing price of the Common Stock on the Trading Market (as reflected on
Nasdaq.com) on the Trading Day immediately prior to the date of this Agreement and (ii) the average Nasdaq official closing price of
the Common Stock on the Trading Market (as reflected on Nasdaq.com) for the five (5) consecutive Trading Days ending on the Trading
Day immediately prior to the date of this Agreement.

 

(c) General. The
Company shall not issue or sell any shares of Common Stock pursuant to this Agreement if such issuance or sale would reasonably be
expected to result in (A) a violation of the Securities Act or (B) a breach of the rules of the Principal Market. The provisions of
this Section 3.3 shall not be implemented in a manner otherwise than in strict conformity with the terms of this Section 3.3 unless
necessary to ensure compliance with the Securities Act and the applicable rules of the Principal Market.

 

Section 3.4. Beneficial Ownership Limitation.
Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell, and the Investor shall not
purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares of Common Stock then
beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated
thereunder), would result in the beneficial ownership by the Investor and its affiliates (on an aggregated basis) of more than 4.99% of
the outstanding voting power or shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the written
or oral request of the Investor, the Company shall promptly (but not later than the next business day on which the Transfer Agent is open
for business) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the
Company shall each cooperate in good faith in the determinations required under this Section 3.4 and the application of this Section 3.4.
The Investor’s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting
effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.
The provisions of this Section 3.4 shall not be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 3.4 unless necessary to properly give effect to the limitations contained in this Section 3.4.

 

    4 

     

    

 

ARTICLE IV 

REPRESENTATIONS, WARRANTIES AND COVENANTS
OF THE INVESTOR 

 

The Investor hereby makes the following representations, warranties
and covenants to the Company:

 

Section 4.1. Organization and Standing of
the Investor. The Investor is a limited liability company duly formed, validly existing and in good standing under the laws of
the State of Delaware.

 

Section 4.2. Authorization and
Power. The Investor has the requisite corporate power and authority to enter into and perform its obligations under this
Agreement and the Registration Rights Agreement and to purchase or acquire the Shares in accordance with the terms hereof. The
execution, delivery and performance by the Investor of this Agreement and the Registration Rights Agreement and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action, and no further consent or
authorization of the Investor or its sole member is required. Each of this Agreement and the Registration Rights Agreement has been
duly executed and delivered by the Investor and constitutes a valid and binding obligation of the Investor enforceable against it in
accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting generally the enforcement of,
creditor’s rights and remedies or by other equitable principles of general application (including any limitation of equitable
remedies).

 

Section 4.3. No Conflicts. The execution,
delivery and performance by the Investor of this Agreement and the Registration Rights Agreement and the consummation by the Investor
of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation of such Investor’s certificate
of formation, limited liability company agreement or other applicable organizational instruments, (ii) conflict with, constitute a default
(or an event which, with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment,
acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument
or obligation to which the Investor is a party or is bound, or (iii) result in a violation of any federal, state, local or foreign statute,
rule, or regulation, or any order, judgment or decree of any court or governmental agency applicable to the Investor or by which any of
its properties or assets are bound or affected, except, in the case of clauses (ii) and (iii), for such conflicts, defaults, terminations,
amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, prohibit or otherwise interfere
with, in any material respect, the ability of the Investor to enter into and perform its obligations under this Agreement and the Registration
Rights Agreement. The Investor is not required under any applicable federal, state or local law, rule or regulation to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver
or perform any of its obligations under this Agreement and the Registration Rights Agreement or to purchase or acquire the Shares in accordance
with the terms hereof; provided, however, that for purposes of the representation made in this sentence, the Investor is
assuming and relying upon the accuracy of the relevant representations and warranties and the compliance with the relevant covenants and
agreements of the Company in the Transaction Documents to which it is a party.

 

Section 4.4. Investment Purpose.
The Investor is acquiring the Shares for its own account, for investment purposes and not with a view towards, or for resale in connection
with, the public sale or distribution thereof, in violation of the Securities Act or any applicable state securities laws; provided,
however, that by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold
any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with,
or pursuant to, a registration statement filed pursuant to the Registration Rights Agreement or an applicable exemption under the Securities
Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell or distribute
any of the Shares. The Investor is acquiring the Shares hereunder in the ordinary course of its business.

 

    5 

     

    

 

Section 4.5. Accredited Investor Status.
The Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

Section 4.6. Reliance on Exemptions.
The Investor understands that the Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements
of U.S. federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor’s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order
to determine the availability of such exemptions and the eligibility of the Investor to acquire the Shares.

 

Section 4.7. Information.
All materials relating to the business, financial condition, management and operations of the Company and materials relating to the offer
and sale of the Shares which have been requested by the Investor have been furnished or otherwise made available to the Investor or its
advisors, including, without limitation, the Commission Documents. The Investor understands that its investment in the Shares involves
a high degree of risk. The Investor is able to bear the economic risk of an investment in the Shares and has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of a proposed investment in the Shares. The Investor
and its advisors have been afforded the opportunity to ask questions of and receive answers from representatives of the Company concerning
the financial condition and business of the Company and other matters relating to an investment in the Shares. Neither such inquiries
nor any other due diligence investigations conducted by the Investor or its advisors, if any, or its representatives shall modify, amend
or affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement or in any
other Transaction Document to which the Company is a party or the Investor’s right to rely on any other document or instrument executed
and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby (including, without limitation
the opinions of the Company’s counsel delivered pursuant to this Agreement and the Registration Rights Agreement). The Investor
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to
its acquisition of the Shares. The Investor understands that it (and not the Company) shall be responsible for its own tax liabilities
that may arise as a result of this investment or the transactions contemplated by this Agreement.

 

Section 4.8. No Governmental Review.
The Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or
made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in the Shares nor have such authorities
passed upon or endorsed the merits of the offering of the Shares.

 

Section 4.9. No General Solicitation.
The Investor is not purchasing or acquiring the Shares as a result of any form of general solicitation or general advertising (within
the meaning of Regulation D) in connection with the offer or sale of the Shares.

 

Section 4.10. Not an Affiliate.
The Investor is not an officer, director or an Affiliate of the Company. During the Investment Period, the Investor will not acquire
for its own account any shares of Common Stock or securities exercisable for or convertible into shares of Common Stock, other than
pursuant to this Agreement; provided, however, that nothing in this Agreement shall prohibit or be deemed to prohibit
the Investor from purchasing, in an open market transaction or otherwise, shares of Common Stock necessary to make delivery by the
Investor in satisfaction of a sale by the Investor of Shares that the Investor anticipated receiving from the Company in connection
with the settlement of a VWAP Purchase if the Company or its transfer agent shall have failed for any reason (other than a failure
of Investor or its Broker-Dealer (as defined below) to set up a DWAC and required instructions) to electronically transfer all of
the Shares subject to such VWAP Purchase to the Investor on the applicable VWAP Purchase Share Delivery Date by crediting the
Investor’s or its designated Broker-Dealer’s account at DTC through its DWAC delivery system in compliance with Section
3.2 of this Agreement. For the avoidance of doubt, the foregoing restriction does not apply to any affiliate of the Investor,
provided that any such purchases do not cause the Investor to violate any applicable Exchange Act requirement, including Regulation
M.

 

    6 

     

    

 

Section 4.11. No Prior Short Sales.
At no time prior to the date of this Agreement has the Investor engaged in or effected, in any manner whatsoever, directly or indirectly,
for its own principal account, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange
Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock that remains
in effect as of the date of this Agreement.

 

Section 4.12. Statutory Underwriter Status.
The Investor acknowledges that it will be disclosed as an “underwriter” and a “selling shareholder” in each Registration
Statement and in any Prospectus contained therein to the extent required by applicable law and to the extent the Prospectus is related
to the resale of Registrable Securities.

 

Section 4.13. Resales of Shares.
The Investor represents, warrants and covenants that it will resell such Shares only pursuant to the Registration Statement in which the
resale of such Shares is registered under the Securities Act, in a manner described under the caption “Plan of Distribution”
in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations.

 

Section 4.14. Residency. The Investor
is a resident of the State of Delaware.

 

ARTICLE V 

REPRESENTATIONS, WARRANTIES AND COVENANTS
OF THE COMPANY 

 

The Company hereby makes the following representations, warranties
and covenants to the Investor:

 

Section 5.1. Organization, Good
Standing and Power. The Company and each of its Subsidiaries are duly organized, validly existing as a corporation or
company and in good standing under the laws of their respective jurisdictions of organization. The Company and each of its
Subsidiaries are duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws
of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses
requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective
properties and to conduct their respective businesses as described in the Commission Documents, except where the failure to be so
qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse
effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings,
properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations of the Company and
the Subsidiaries taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (a
 “Material Adverse Effect”).

 

Section 5.2. Subsidiaries. The subsidiaries
set forth on Schedule 1 (collectively, the “Subsidiaries”), are the Company’s only significant
subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission). Except as set forth in the
Commission Documents, the Company owns, directly or indirectly, all of the equity interests of the Subsidiaries free and clear of any
lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests of the Subsidiaries
are validly issued and are fully paid, nonassessable and free of preemptive and similar rights. Each Subsidiary of the Company has been
duly formed or organized, is validly existing under the applicable laws of its jurisdiction of incorporation or organization and has the
organizational power and authority to own, lease and operate its assets and properties and to conduct its business as it is now being
conducted. Each of the Company’s Subsidiaries is duly licensed or qualified and in good standing (or equivalent status as applicable)
as a foreign corporation (or other entity, if applicable) in each jurisdiction in which the assets owned or leased by it or the character
of its activities require it to be licensed or qualified or in good standing (or equivalent status as applicable), except where the failure
to be so licensed or qualified, individually or in the aggregate, has not had and would not be expected to have a Material Adverse Effect.

 

    7 

     

    

 

Section 5.3. Authorization, Enforcement.
The Company has the requisite corporate power and authority to enter into and perform its obligations under each of the Transaction Documents
to which it is a party and to issue the Shares in accordance with the terms hereof and thereof. Except for approvals of the Company’s
Board of Directors or a committee thereof as may be required in connection with any issuance and sale of Shares to the Investor hereunder
(which approvals shall be obtained prior to the delivery of any VWAP Purchase Notice), the execution, delivery and performance by the
Company of each of the Transaction Documents to which it is a party and the consummation by it of the transactions contemplated hereby
and thereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of the Company,
its Board of Directors or its stockholders is required. Each of the Transaction Documents to which the Company is a party has been duly
executed and delivered by the Company and constitutes a valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights
and remedies or by other equitable principles of general application (including any limitation of equitable remedies).

 

Section 5.4. Capitalization.
The authorized capital stock of the Company and the shares thereof issued and outstanding were as set forth in the Commission
Documents as of the dates reflected therein. All of the outstanding shares of Common Stock have been duly authorized and validly
issued and are fully paid and non-assessable. Except as set forth in the Commission Documents, this Agreement and the Registration
Rights Agreement, there are no agreements or arrangements under which the Company is obligated to register the sale of any
securities under the Securities Act. Except as set forth in the Commission Documents, no shares of Common Stock are entitled to
preemptive rights and there are no outstanding debt securities and no contracts, commitments, understandings, or arrangements by
which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or
exchangeable for, any shares of capital stock of the Company other than those issued or granted in the ordinary course of business
pursuant to the Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer
restrictions contained in agreements entered into by the Company to sell restricted securities or as set forth in the Commission
Documents, the Company is not a party to, and it has no Knowledge of, any agreement restricting the voting or transfer of any shares
of the capital stock of the Company. Except as set forth in the Commission Documents, there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by this Agreement or any of the other Transaction Documents or
the consummation of the transactions described herein or therein. The Company has filed with the Commission true and correct copies
of the Company’s Memorandum of Association as in effect on the Closing Date (the “Charter”), and the
Company’s Amended and Restated Bye-laws as in effect on the Closing Date (the “Bye-laws”).

 

Section 5.5. Issuance of Shares.
The Commitment Shares have been and the Shares to be issued under this Agreement have been, or with respect to Shares to be purchased
by the Investor pursuant to a particular VWAP Purchase Notice, will be, prior to the delivery to the Investor hereunder of such VWAP Purchase
Notice, duly and validly authorized by all necessary corporate action on the part of the Company. The Commitment Shares, when issued to
the Investor in accordance with the Agreement, and the Shares, if and when issued and sold against payment therefor in accordance with
this Agreement, shall be validly issued and outstanding, fully paid and non-assessable and free from all liens, charges, taxes, security
interests, encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof,
and the Investor shall be entitled to all rights accorded to a holder of Common Stock. At or prior to Commencement, the Company shall
have duly authorized and reserved a number of shares of Common Stock equal to the Exchange Cap for issuance and sale as Shares to the
Investor pursuant to VWAP Purchases that may be effected by the Company, in its sole discretion, from time to time from and after the
Commencement Date, pursuant to this Agreement.

 

    8 

     

    

 

Section 5.6. No Conflicts. The
execution, delivery and performance by the Company of each of the Transaction Documents to which it is a party and the consummation
by the Company of the transactions contemplated hereby and thereby do not and shall not (i) result in a violation of any provision
of the Company’s Charter or Bylaws, (ii) conflict with or constitute a default (or an event which, with notice or lapse of
time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of,
any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which
the Company or any of its Subsidiaries is a party or is bound, (iii) create or impose a lien, charge or encumbrance on any property
or assets of the Company or any of its Subsidiaries under any agreement or any commitment to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of their respective properties
or assets is subject, iv ) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment
or decree applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its
Subsidiaries are bound or affected (including federal and state securities laws and regulations and the rules and regulations of the
Principal Market or applicable Principal Market), except, in the case of clauses (ii) and (iii), for such conflicts, defaults,
terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and violations as would not, individually or in
the aggregate, reasonably be expected to result in a Material Adverse Effect or that have been waived. Except as specifically
contemplated by this Agreement or the Registration Rights Agreement and as required under the Securities Act, any applicable state
securities laws and applicable rules of the Principal Market, the Company is not required under any federal, state or local rule or
regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental
agency (including, without limitation, the Principal Market) in order for it to execute, deliver or perform any of its obligations
under the Transaction Documents to which it is a party, or to issue the Shares to the Investor in accordance with the terms hereof
and thereof (other than such consents, authorizations, orders, filings or registrations as have been obtained or made prior to the
Closing Date); provided, however, that, for purposes of the representation made in this sentence, the Company is
assuming and relying upon the accuracy of the representations and warranties of the Investor in this Agreement and the compliance by
it with its covenants and agreements contained in this Agreement and the Registration Rights Agreement.

 

Section 5.7. Commission Documents, Financial
Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants.

 

(a)
Since October 22, 2021, the Company has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under
the Exchange Act) all filings required to be filed with or furnished to the Commission by the Company under the Securities Act or
the Exchange Act, including those required to be filed with or furnished to the Commission under Section 13(a) or Section 15(d) of
the Exchange Act. As of the date of this Agreement, no Subsidiary of the Company is required to file or furnish any report,
schedule, registration, form, statement, information or other document with the Commission. As of its filing date, each Commission
Document filed with or furnished to the Commission prior to the Closing Date complied in all material respects with the requirements
of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable
to it, and, as of its filing date (or, if amended or superseded by a filing prior to the Closing Date, on the date of such amended
or superseded filing). Each Registration Statement, on the date it is filed with the Commission, on the date it is declared
effective by the Commission and on each VWAP Purchase Date shall comply in all material respects with the requirements of the
Securities Act (including, without limitation, Rule 415 under the Securities Act) and shall not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein
not misleading, except that this representation and warranty shall not apply to statements in or omissions from such Registration
Statement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by
or on behalf of the Investor expressly for use therein. The Prospectus and each Prospectus Supplement required to be filed pursuant
to this Agreement or the Registration Rights Agreement after the Closing Date, when taken together, on its date and on each VWAP
Purchase Date shall comply in all material respects with the requirements of the Securities Act (including, without limitation, Rule
424(b) under the Securities Act) and shall not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading, except that this representation and warranty shall not apply to statements in or omissions from the
Prospectus or any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished
to the Company in writing by or on behalf of the Investor expressly for use therein. The statistical, demographic and market-related
data included in the Registration Statement and Prospectus are based on or derived from sources that the Company believes to be
reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such
sources. Each Commission Document (other than the Initial Registration Statement or any New Registration Statement, or the
Prospectus included therein or any Prospectus Supplement thereto) to be filed with or furnished to the Commission after the Closing
Date and incorporated by reference in the Initial Registration Statement or any New Registration Statement, or the Prospectus
included therein or any Prospectus Supplement thereto required to be filed pursuant to this Agreement or the Registration Rights
Agreement (including, without limitation, the Current Report), when such document is filed with or furnished to the Commission and,
if applicable, when such document becomes effective, as the case may be, shall comply in all material respects with the requirements
of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable
to it. The Company has delivered or made available to the Investor via EDGAR or otherwise true and complete copies of all comment
letters and substantive correspondence received by the Company from the Commission relating to the Commission Documents filed with
or furnished to the Commission as of the Closing Date, together with all written responses of the Company thereto in the form such
responses were filed via EDGAR. There are no outstanding or unresolved comments or undertakings in such comment letters received by
the Company from the Commission. The Commission has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company under the Securities Act or the Exchange Act.

 

    9 

     

    

 

(b) The consolidated financial
statements of the Company included or incorporated by reference in the Commission Documents, together with the related notes and
schedules, present fairly, in all material respects, the consolidated financial position of the Company and its then consolidated
subsidiaries as of the dates indicated, and the consolidated results of operations, cash flows and changes in stockholders’
equity of the Company and its then consolidated subsidiaries for the periods specified and have been prepared in compliance with the
published requirements of the Securities Act and the Exchange Act, as applicable, and in conformity with generally accepted
accounting principles in the United States (“GAAP”) applied on a consistent basis. The summary
consolidated financial data included or incorporated by reference in the Commission Documents present fairly the information shown
therein and have been compiled on a basis consistent with that of the financial statements included or incorporated by reference in
the Commission Documents, as of and at the dates indicated. The pro forma condensed combined financial statements and the pro forma
combined financial statements and any other pro forma financial statements or data included or incorporated by reference in the
Commission Documents comply with the requirements of Regulation S-X of the Securities Act, including, without limitation, Article 11
thereof, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable, the pro forma
adjustments used therein are appropriate to give effect to the circumstances referred to therein and the pro forma adjustments have
been properly applied to the historical amounts in the compilation of those statements and data. There are no financial statements
(historical or pro forma) that are required to be included or incorporated by reference in the Commission Documents that are not
included or incorporated by reference as required. The Company and the Subsidiaries do not have any material liabilities or
obligations, direct or contingent (including any off-balance sheet obligations or any “variable interest entities” as
that term is used in Accounting Standards Codification Paragraph 810-10-25-20), not described in Commission Documents which are
required to be described in the Commission Documents. All disclosures contained or incorporated by reference in the Commission
Documents, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the
Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included in the Commission Documents
fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s
rules and guidelines applicable thereto.

 

(c) Ernst & Young LLP, (the
 “Ernst & Young”) whose report on the consolidated financial statements of the Company as of December
31, 2020 and 2019, and for each of the two years in the period ended December 31, 2020 included in the Company’s registration
statement on Form S-1 (File No. 333-257964), are and, during the periods covered by their report, were an independent public
accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the
Company’s knowledge, the Ernst & Young is not in violation of the auditor independence requirements of the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”) with respect to the Company.

 

(d) Marcum LLP, (the
 “Marcum”) whose report on the consolidated financial statements of Virtuoso Acquisition Corp. as of
December 31, 2020 and for the period from August 25, 2020 (inception) through December 31, 2020 included in the Company’s
registration statement on Form S-1 (No. 333-257964), are and, during the periods covered by their report, were an independent public
accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the
Company’s knowledge, Marcum is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act with
respect to the Company.

 

    10 

     

    

 

(e)
Except as disclosed in the Commission Documents, there is and has been no failure on the part of the Company or any of the
Company’s directors or officers, in their capacities as such, to comply in all material respects with any applicable
provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each of the principal executive officer
and the principal financial officer of the Company (or each former principal executive officer of the Company and each former
principal financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the
Sarbanes-Oxley Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it or
furnished by it to the Commission. For purposes of the preceding sentence, “principal executive officer” and
 “principal financial officer” shall have the meanings given to such terms in the Sarbanes-Oxley Act. The Company and the
Subsidiaries will maintain and keep accurate books and records reflecting their assets and maintain internal accounting controls in
a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles and including those policies and
procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the
transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as
necessary to permit the preparation of the Company’s consolidated financial statements in accordance with generally accepted
accounting principles, (iii) that receipts and expenditures of the Company are being made only in accordance with
management’s and the Company’s directors’ authorization, and (iv) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a
material effect on its financial statements. The Company and the Subsidiaries will maintain such controls and other procedures,
including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations
thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission’s rules and forms, including, without limitation, controls and procedures designed to ensure that information
required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and
communicated to the Company’s management, including its principal executive officer and principal financial officer, or
persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that
material information relating to the Company or the Subsidiaries is made known to them by others within those entities, particularly
during the period in which such periodic reports are being prepared.

 

Section 5.8. No Material Adverse
Effect; Absence of Certain Changes. Subsequent to the respective dates as of which information is given in the Commission
Documents (including any document deemed incorporated by reference therein), there has not been (i) any Material Adverse Effect or
the occurrence of any development that the Company reasonably expects will result in a Material Adverse Effect, (ii) any transaction
which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent
(including any off-balance sheet obligations), incurred by the Company or any Subsidiary, which is material to the Company and the
Subsidiaries taken as a whole, (iv) any material change in the capital stock (other than (A) the grant of additional awards under
the Company’s existing equity incentive plans, (B) changes in the number of outstanding Common Stock of the Company due to the
issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on
the date hereof, (C) as described in a proxy statement filed on Schedule 14A or a Registration Statement on Form S-4, or (D)
otherwise publicly announced on a Form 8-K or Company press release) or outstanding long-term indebtedness of the Company or any of
its Subsidiaries or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or any
Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in the Commission Documents
(including any document deemed incorporated by reference therein).

 

Section 5.9. No Material Defaults.
Neither the Company nor any of its Subsidiaries has defaulted on any installment on indebtedness for borrowed money or on any rental on
one or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect. The Company has
not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act indicating that it (i) has failed to pay any dividend or sinking
fund installment on preferred shares or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one
or more long-term leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect. Neither the Company
nor any of its Subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default,
and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any
of the property or assets of the Company or any of its Subsidiaries are subject; or (iii) in violation of any law or statute or any
judgment, order, rule or regulation of any Governmental Authority, except, in the case of each of clauses (ii) and (iii) above, for any
such violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.

 

    11 

     

    

 

Section 5.10. No Preferential Rights.
 Except as set forth in the Commission Documents or provided hereunder, (i) no Person, has the right, contractual or otherwise,
to cause the Company to issue or sell to such Person any Common Stock or shares of any other capital stock or other securities of the
Company, (ii) no Person has any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other rights
(whether pursuant to a “poison pill” provision or otherwise) to purchase any Common Stock or shares of any other capital stock
or other securities of the Company, (iii)  no Person has the right to act as an underwriter or as a financial advisor to the Company
in connection with the offer and sale of the Common Stock offered hereunder, and (iv) no Person has the right, contractual or otherwise,
to require the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities
of the Company, or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby,
whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Shares as contemplated thereby or
otherwise.

 

Section 5.11. Material Contracts.
Neither the Company nor any of its Subsidiaries is in material breach of or default in any respect under the terms of any Material Contract
and, to the Knowledge of the Company, as of the date hereof, no other party to any Material Contract is in material breach of or default
under the terms of any Company Material Contract. Each agreement between the Company and a third party is in full force and effect and
is a valid and binding obligation of the Company or the Subsidiary of the Company that is party thereto and, to the Knowledge of the Company,
is a valid and binding obligation of each other party thereto. The Company has not received any written notice of the intention of any
other party to a Material Contract to terminate for default, convenience or otherwise, or not renew, any Material Contract.

 

Section 5.12. Solvency. The Company
has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to Title 11 of the United States
Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company have any Knowledge that its
creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief
under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for the relief of debtors. The Company
is financially solvent and is generally able to pay its debts as they become due. The Company’s Quarterly Report on Form 10-Q for
its fiscal quarter ended September 30, 2021 sets forth, as of September 30, 2021, all outstanding secured and unsecured Indebtedness of
the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments through such date. For the purposes of this
Agreement, “Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than
trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements, indemnities and other contingent
obligations in respect of Indebtedness of others in excess of $100,000, whether or not the same are or should be reflected in the Company’s
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of $100,000 due under leases
required to be capitalized in accordance with GAAP. There is no existing or continuing default or event of default in respect of any Indebtedness
of the Company or any of its Subsidiaries.

 

Section 5.13. Real Property; Intellectual
Property.

 

(a) Except as set forth in the
Commission Documents, the Company and its Subsidiaries have good and marketable title in fee simple to all items of real property
owned by them, good and valid title to all personal property described in the Commission Documents as being owned by them that are
material to their businesses, in each case free and clear of all liens, encumbrances and claims, except those matters that (i) do
not materially interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries or
(ii) would not, individually or in the aggregate, have a Material Adverse Effect. Any real or personal property described in the
Commission Documents as being leased by the Company and any of its Subsidiaries is held by them under valid, existing and
enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by
the Company or any of its Subsidiaries or (B) would not be reasonably expected, individually or in the aggregate, to have a Material
Adverse Effect. Each of the properties of the Company and its Subsidiaries complies with all applicable codes, laws and regulations
(including, without limitation, building and zoning codes, laws and regulations and laws relating to access to such properties),
except if and to the extent disclosed in the Commission Documents or except for such failures to comply that would not, individually
or in the aggregate, reasonably be expected to interfere in any material respect with the use made and proposed to be made of such
property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect. None of the Company or its subsidiaries
has received from any Governmental Authorities any notice of any condemnation of, or zoning change affecting, the properties of the
Company and its Subsidiaries, and the Company knows of no such condemnation or zoning change which is threatened, except for such
that would not reasonably be expected to interfere in any material respect with the use made and proposed to be made of such
property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect, individually or in the aggregate.

 

    12 

     

    

 

(b) Except as disclosed in the
Commission Documents, the Company and its Subsidiaries own, possess, license or have other rights to use all foreign and domestic
patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses,
inventions, trade secrets, technology, Internet domain names, know-how and other intellectual property (collectively, the
 “Intellectual Property”), necessary for the conduct of their respective businesses as now conducted except
to the extent that the failure to own, possess, license or otherwise hold adequate rights to use such Intellectual Property would
not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in the Commission Documents (i) there are
no rights of third parties to any such Intellectual Property owned by the Company and its Subsidiaries; (ii) to the Company’s
knowledge, there is no infringement by third parties of any such Intellectual Property; (iii) there is no pending or, to the
Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s and its
Subsidiaries’ rights in or to any such Intellectual Property, and the Company is unaware of any facts which could form a
reasonable basis for any such action, suit, proceeding or claim; (iv) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property; (v)
there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company
and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade secret or other proprietary rights of
others; (vi) to the Company’s knowledge, there is no third-party U.S. patent or published U.S. patent application which
contains claims for which an Interference Proceeding (as defined in 35 U.S.C. § 135) has been commenced against any patent or
patent application described in the Commission Documents as being owned by or licensed to the Company; and (vii) the Company and its
Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company
or such Subsidiary, and all such agreements are in full force and effect, except, in the case of any of clauses (i)-(vii) above, for
any such rights infringement by third parties or any such pending or threatened suit, action, proceeding or claim as would not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company and its Subsidiaries
have taken commercially reasonable efforts to maintain the confidentiality of all material trade secrets and other material
confidential information of the Company and its Subsidiaries and any confidential information owned by any Person to whom the
Company or any of its Subsidiaries has a written confidentiality obligation.

 

Section 5.14. Actions Pending.
Except as disclosed in the Commission Documents, there are no actions, suits or proceedings by or before any Governmental Authority
pending, nor, to the Company’s knowledge, any audits or investigations by or before any Governmental Authority to which the
Company or a Subsidiary is a party or to which any property of the Company or any of its Subsidiaries is the subject that,
individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect and, to the Company’s
knowledge, no such actions, suits, proceedings, audits or investigations are threatened or contemplated by any Governmental
Authority or threatened by others; and (i) there are no current or pending audits or investigations, actions, suits or
proceedings by or before any Governmental Authority that are required under the Securities Act to be described in the Commission
Documents that are not so described; and (ii) there are no contracts or other documents that are required under the Securities
Act to be filed as exhibits to the Commission Documents that are not so filed.

 

Section 5.15. Compliance with Law.
The Company and each of its Subsidiaries are in compliance with all applicable laws, regulations and statutes (including all environmental
laws and regulations) in the jurisdictions in which it carries on business, except where failure to be so in compliance would not reasonably
be expected to result in a Material Adverse Effect; the Company has not received a notice of non-compliance, nor knows of, nor has reasonable
grounds to know of, any facts that could give rise to a notice of non-compliance with any such laws, regulations and statutes, and is
not aware of any pending change or contemplated change to any applicable law or regulation or governmental position; in each case that
would reasonably be expected to materially adversely affect the business of the Company or the business or legal environment under which
the Company operates.

 

Section 5.16. Certain Fees. Except
as disclosed to the Investors, neither the Company nor any of its Subsidiaries has incurred any liability for any finder’s fees,
brokerage commissions or similar payments in connection with the transactions herein contemplated.

 

    13 

     

    

 

Section 5.17. Disclosure. The Company
confirms that neither it nor any other Person acting on its behalf has provided the Investor or any of its agents, advisors or counsel
with any information that constitutes or could reasonably be expected to constitute material, nonpublic information concerning the Company
or any of its Subsidiaries, other than the existence of the transactions contemplated by the Transaction Documents. The Company understands
and confirms that the Investor will rely on the foregoing representations in effecting resales of Shares under the Registration Statement.

 

Section 5.18. Broker/Dealer Relationships.
Neither the Company nor any of the Subsidiaries (i) is required to register as a “broker” or “dealer”
in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls
or is a “person associated with a member” or “associated person of a member” (within the meaning set forth in
the FINRA Manual).

 

Section 5.19. Disclosure Controls. The
Company and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with
management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company’s
internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal
control over financial reporting (other than as set forth in the Commission Documents). Since the date of the latest audited
financial statements of the Company included in the Commission Documents, there has been no change in the Company’s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting (other than as set forth in the Commission Documents). The Company has established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such
disclosure controls and procedures to ensure that material information relating to the Company and each of its Subsidiaries is made
known to the certifying officers by others within those entities, particularly during the period in which the Company’s Annual
Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company’s certifying
officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of a date within 90 days
prior to the filing date of the Form 10-K for the fiscal year most recently ended (such date, the “Evaluation
Date”). The Company presented in its Form 10-K for the fiscal year most recently ended the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the
Evaluation Date and the disclosure controls and procedures are effective. Since the Evaluation Date, there have been no significant
changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Securities
Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal
controls.

 

    14 

     

    

 

Section 5.20. Permits. Except as
disclosed in the Commission Documents, the Company and its Subsidiaries have made all filings, applications and submissions required by,
possesses and is operating in compliance with, all approvals, licenses, certificates, certifications, clearances, consents, grants, exemptions,
marks, notifications, orders, permits and other authorizations issued by, the appropriate federal, state or foreign Governmental Authority
for the ownership or lease of their respective properties or to conduct its businesses as described in the Commission Documents (collectively,
 “Permits”), except for such Permits the failure of which to possess, obtain or make the same would not reasonably
be expected to have a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of all
such Permits, except where the failure to be in compliance would not have a Material Adverse Effect; all of the Permits are valid and
in full force and effect, except where any invalidity, individually or in the aggregate, would not be reasonably expected to have a Material
Adverse Effect; and neither the Company nor any of its Subsidiaries has received any written notice relating to the limitation, revocation,
cancellation, suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect, or has any reason to believe that any such
license, certificate, permit or authorization will not be renewed in the ordinary course except where the failure to obtain any such renewal
would not, individually or in the aggregate, have a Material Adverse Effect. This Section 5.21 does not relate to environmental matters,
such items being the subject of Section 5.22.

 

Section 5.21. Environmental
Compliance. Except as set forth in the Commission Documents, the Company and its Subsidiaries (i) are in compliance
with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(collectively, “Environmental Laws”); (ii) have received and are in compliance with all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as described
in the Commission Documents; and (iii) have not received notice of any actual or potential liability for the investigation or
remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case
of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other
approvals or liability as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    15 

     

    

 

 

Section 5.22. No Improper Practices.
(i) Neither the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary nor, to the
Company’s Knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has, in the past five
years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation
of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign
office or other person charged with similar public or quasi-public duty in violation of any applicable law or of the character required
to be disclosed in the Commission Documents; (ii) no relationship, direct or indirect, exists between or among the Company or any
Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of the Company or any Subsidiary,
on the other hand, that is required by the Securities Act to be described in the Commission Documents that is not so described; (iii) no
relationship, direct or indirect, exists between or among the Company or the Subsidiaries or any affiliate of them, on the one hand, and
the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand, that is required by the rules of FINRA to
be described in the Commission Documents that is not so described; (iv) except as described in the Commission Documents, there are
no material outstanding loans or advances or material guarantees of indebtedness by the Company or any Subsidiary to or for the benefit
of any of their respective officers or directors or any of the members of the families of any of them; and (v) the Company has not offered,
or caused any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A) a customer or supplier
of the Company or the Subsidiaries to alter the customer’s or supplier’s level or type of business with the Company or any
Subsidiary or (B) a trade journalist or publication to write or publish favorable information about the Company or the Subsidiaries
or any of their respective products or services, and, (vi) neither the Company nor the Subsidiaries nor any director, officer or employee
of the Company or any Subsidiary nor, to the Company’s Knowledge, any agent, affiliate or other person acting on behalf of the Company
or any Subsidiary has (A) violated or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as
amended, or any other applicable anti-bribery or anti-corruption law (collectively, “Anti-Corruption Laws”),
(B) promised, offered, provided, attempted to provide or authorized the provision of anything of value, directly or indirectly, to any
person for the purpose of obtaining or retaining business, influencing any act or decision of the recipient, or securing any improper
advantage; or (C) made any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any Anti-Corruption
Laws.

 

Section 5.23. AML Compliance. The
operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial
record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority
(collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any
Governmental Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to
the knowledge of the Company, threatened.

 

    16 

     

    

 

Section 5.24. Off-Balance Sheet Arrangements.
There are no transactions, arrangements and other relationships between and/or among the Company, and/or any of its affiliates and any
unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each, an “Off-Balance
Sheet Transaction”) that could reasonably be expected to affect materially the Company’s liquidity or the availability
of or requirements for its capital resources, including those Off-Balance Sheet Transactions described in the Commission’s Statement
about Management’s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321;
FR-61), required to be described in the Commission Documents which have not been described as required.

 

Section 5.25. Transactions With Affiliates.
No relationship, direct or indirect, exists between or among the Company or any of its Subsidiaries on the one hand, and the directors,
officers, trustees, managers, stockholders, partners, customers or suppliers of the Company or any of the Subsidiaries on the other hand,
which would be required by the Securities Act or the Exchange Act to be disclosed in the Commission Documents, which is not so disclosed.

 

Section 5.26. Labor Disputes. None
of the Company nor any of its Subsidiaries is bound by or subject to any collective bargaining or similar agreement with any labor union,
and, to the Knowledge of the Company, none of the employees, representatives or agents of the Company or any of its Subsidiaries is represented
by any labor union. The Company and its Subsidiaries have complied with all employment laws applicable to employees of the Company and
its Subsidiaries, except where non-compliance with any such employment laws would not have a Material Adverse Effect. No labor disturbance
by or dispute with employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is threatened which
would result in a Material Adverse Effect.

 

Section 5.27. Use of Proceeds. The
proceeds from the sale of the Shares by the Company to Investor shall be used by the Company in the manner as will be set forth in the
Prospectus included in any Registration Statement (and any post-effective amendment thereto) and any Prospectus Supplement thereto filed
pursuant to the Registration Rights Agreement.

 

Section 5.28. Investment Company Act Status.
The Company is not, and as a result of the consummation of the transactions contemplated by the Transaction Documents and the application
of the proceeds from the sale of the Shares as will be set forth in the Prospectus included in any Registration Statement (and any post-effective
amendment thereto) and any Prospectus Supplement thereto filed pursuant to the Registration Rights Agreement the Company will not be an
 “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

Section 5.29. Margin Rules.
Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described in the
Commission Documents will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other
regulation of such Board of Governors.

 

    17 

     

    

 

Section 5.30. Taxes. The Company
and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required to be filed and paid
all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith,
except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed in or contemplated
by the Commission Documents, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had,
or would have, individually or in the aggregate, reasonably expected to be a Material Adverse Effect. The Company has no knowledge of
any federal, state or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against
it which would reasonably have a Material Adverse Effect.

 

Section 5.31. ERISA. To the knowledge
of the Company, (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ERISA”), that is maintained, administered or contributed to by the Company or any
of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in material compliance
with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and
the Internal Revenue Code of 1986, as amended (the “Code”); and (ii) no prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect
to any such plan excluding transactions effected pursuant to a statutory or administrative exemption other than in the case of (i) and
(ii) above as would not have a Material Adverse Effect.

 

Section 5.32. Stock Transfer Taxes.
All stock transfer or other taxes (other than income taxes) which are required to be paid in connection with the sale and transfer of
the Shares to be sold hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes
will be or will have been fully complied with.

 

Section 5.33. Insurance. The Company
and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the Company and each of its
Subsidiaries reasonably believe are adequate for the conduct of their properties and as is customary for companies engaged in similar
businesses in similar industries.

 

Section 5.34. Exemption from Registration.
Subject to, and in reliance on, the representations, warranties and covenants made herein by the Investor, the offer and sale of the Shares
in accordance with the terms and conditions of this Agreement is exempt from the registration requirements of the Securities Act pursuant
to Section 4(a)(2) and/or Rule 506(b) of Regulation D; provided, however, that at the request of and with the express agreements
of the Investor (including, without limitation, the representations, warranties and covenants of Investor set forth in Section 4.9 through
4.13), the Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued
to the Investor or its designee only as DWAC Shares and will not bear legends noting restrictions as to resale of such securities under
federal or state securities laws, nor will any such securities be subject to stop transfer instructions.

 

    18 

     

    

 

Section 5.35. No General Solicitation or
Advertising. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person acting on its or their behalf, has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or
sale of the Shares.

 

Section 5.36. No Integrated Offering.
None of the Company, its Subsidiaries or any of their Affiliates, nor any Person acting on their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of
the issuance of any of the Shares under the Securities Act, whether through integration with prior offerings or otherwise, or cause this
offering of the Shares to require approval of stockholders of the Company under any applicable stockholder approval provisions, including,
without limitation, under the rules and regulations of the Principal Market. None of the Company, its Subsidiaries, their Affiliates nor
any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would require registration
of the issuance of any of the Shares under the Securities Act or cause the offering of any of the Shares to be integrated with other offerings.

 

Section 5.37. Dilutive Effect. The
Company is aware and acknowledges that issuance of the Shares could cause dilution to existing stockholders and could significantly increase
the outstanding number of shares of Common Stock. The Company further acknowledges that its obligation to issue the Shares to be purchased
by the Investor pursuant to a VWAP Purchase is, upon the Company’s delivery to the Investor of a VWAP Purchase Notice for a VWAP
Purchase in accordance with this Agreement, absolute and unconditional following the delivery of such VWAP Purchase Notice to the Investor,
regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Company.

 

Section 5.38. Manipulation of Price.
Neither the Company nor any of its officers, directors or Affiliates has, and, to the Knowledge of the Company, no Person acting on their
behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or to result in the stabilization or manipulation
of the price of any security of the Company, or which caused or resulted in, or which would in the future reasonably be expected to cause
or result in, the stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale
of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Shares, or (iii)
paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. Neither the
Company nor any of its officers, directors or Affiliates will during the term of this Agreement, and, to the Knowledge of the Company,
no Person acting on their behalf will during the term of this Agreement, take any of the actions referred to in the immediately preceding
sentence.

 

Section 5.39. Listing and Maintenance
Requirements; DTC Eligibility. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company
has taken no action designed to, or which to its Knowledge is likely to have the effect of, terminating the registration of the
Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not received notice from the Principal Market to the effect that the Company is not in compliance
with the listing or maintenance requirements of the Principal Market. The Common Stock is eligible for participation in the DTC book
entry system and has shares on deposit at DTC for transferred electronically to third parties via DTC through its Deposit/Withdrawal
at Custodian (“DWAC”) delivery system. The Company has not received notice from DTC to the effect that a
suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by
DTC with respect to the Common Stock is being imposed or is contemplated.

 

    19 

     

    

 

Section 5.40. Application of Takeover Protections.
The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under
the Company’s Charter or the laws of its state of incorporation that is or could become applicable to the Investor as a result of
the Investor and the Company fulfilling their respective obligations or exercising their respective rights under the Transaction Documents
(as applicable), including, without limitation, as a result of the Company’s issuance of the Shares and the Investor’s ownership
of the Shares.

 

Section 5.41. OFAC. Neither the Company
nor any of its Subsidiaries (collectively, the “Entity”), nor any director, officer, employee, agent, affiliate
or representative of the Company, is a Person that is, or is owned or controlled by a Person that is (i) the subject of any sanctions
administered or enforced by the (“OFAC”), the United Nations Security Council, the European Union, Her Majesty’s
Treasury, or other relevant sanctions authorities, including, without limitation, designation on OFAC’s Specially Designated Nationals
and Blocked Persons List or OFAC’s Foreign Sanctions Evaders List or other relevant sanctions authority (collectively, “Sanctions”),
nor (ii) located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with
that country or territory (including, without limitation, the Crimea region of the Ukraine, Cuba, Iran, North Korea, Sudan and Syria (the
 “Sanctioned Countries”)). The Entity will not, directly or indirectly, use the proceeds from the sale of Shares,
or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person (a) to fund or
facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation,
is the subject of Sanctions or is a Sanctioned Country, or (b) in any other manner that will result in a violation of Sanctions by any
Person (including any Person participating in the transactions contemplated by this agreement, whether as underwriter, advisor, investor
or otherwise). For the past five years, the Entity has not engaged in, and is now not engaged in, any dealings or transactions with any
Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or was a Sanctioned
Country.

 

Section 5.42. Information Technology;
Compliance with Data Privacy Laws. The Company and its Subsidiaries comply in all respects with (i) all applicable
Privacy/Data Security Laws, (ii) any applicable privacy or other policies of the Company or any of its Subsidiaries, respectively,
concerning the collection, dissemination, storage or use of Personal Information or other Business Data, (iii) industry standards to
which the Company or any of its Subsidiaries, respectively, purports to adhere, and (iv) all contractual commitments that the
Company or any of its Subsidiaries has entered into with respect to privacy and/or data security (collectively, the
 “Data Security Requirements”), except where the failure to so comply would not reasonably be expected to
have a Material Adverse Effect. The Company and its Subsidiaries have implemented commercially reasonable data security safeguards
designed to protect the security and integrity of the Business Systems and Business Data. Except as has not resulted in a Material
Adverse Effect, to the Company’s Knowledge, neither the Company nor any Subsidiary has experienced any data security breaches,
unauthorized access or use of any of the Business Systems, or unauthorized acquisition, destruction, damage, disclosure, loss,
corruption, alteration, or use of any Business Data; or been subject to or received written notice of any audits, proceedings
or investigations by any Governmental Authority or any customer, or received any material claims or complaints regarding the
collection, dissemination, storage or use of Personal Information, or the violation of any applicable Data Security
Requirements.

 

    20 

     

    

 

Section 5.43. Acknowledgement Regarding
Investor’s Acquisition of Shares; Affiliate Relationships. The Company acknowledges and agrees, to the fullest extent
permitted by law, that the Investor is acting solely in the capacity of an arm’s-length purchaser with respect to this
Agreement and the transactions contemplated by the Transaction Documents, and Cantor Fitzgerald & Co.
(“CF&CO”) is acting as a representative of the Investor in connection with the transactions
contemplated by the Transaction Documents, and of no other party, including the Company. The Company further acknowledges that while
the Investor will be deemed to be a statutory “underwriter” with respect to the Transaction in accordance with
interpretive positions of the Staff of the U.S. Securities and Exchange Commission (the “SEC”), the
Investor has represented it is a “trader” that is not required to register with the SEC as a broker-dealer under Section
15(a) of the Securities Exchange Act of 1934. The Company further acknowledges that the Investor and its representatives are not
acting as a financial advisor or fiduciary of the Company (or in any similar capacity, except as noted above) with respect to this
Agreement and the transactions contemplated by the Transaction Documents, and any advice given by the Investor or any of its
representatives (including CF&CO) or agents in connection therewith is merely incidental to the Investor’s acquisition of
the Shares. The Company further represents to the Investor that the Company’s decision to enter into the Transaction Documents
to which it is a party has been based solely on the independent evaluation of the transactions contemplated thereby by the Company
and its representatives. The Company acknowledges and agrees that the Investor has not made and does not make any representations or
warranties with respect to the transactions contemplated by the Transaction Documents other than those specifically set forth in
Article IV. Affiliates of the Investor, including CF&CO, engage in a wide range of activities for their own accounts and the
accounts of customers, including corporate finance, mergers and acquisitions, merchant banking, equity and fixed income sales,
trading and research, derivatives, foreign exchange, futures, asset management, custody, clearance and securities lending. In the
course of its business, affiliates of Investor may, directly or indirectly, hold long or short positions, trade and otherwise
conduct such activities in or with respect to debt or equity securities and/or bank debt of, and/or derivative products relating to,
the Company. Any such position will be created, and maintained, independently of the position Investor takes in the Company, and
Investor. In addition, at any given time affiliates of Investor, including CF&CO, may have been and/or be engaged by one or more
entities that may be competitors with, or otherwise adverse to, the Company in matters unrelated to the transactions contemplated by
the Transaction Documents, and affiliates of Investor, including CF&CO may have or may in the future provide investment banking
or other services to the Company in matters unrelated to the transactions contemplated by the Transaction Documents. Activities of
any of Investor’s affiliates performed on behalf of the Company may give rise to actual or apparent conflicts of interest
given Investor’s potentially competing interests with those of the Company. The Company expressly acknowledges the benefits it
receives from Investor’s participation in the transactions contemplated by the Transaction Documents, on the one hand, and
Investor’s affiliates’ activities, if any, on behalf of the Company unrelated to the transactions contemplated by the
Transaction Documents, on the other hand, and understands the conflict or potential conflict of interest that may arise in this
regard, and has consulted with such independent advisors as it deems appropriate in order to understand and assess the risks
associated with these potential conflicts of interest. Consistent with applicable legal and regulatory requirements, applicable
affiliates of the Investor have adopted policies and procedures to establish and maintain the independence of their research
departments and personnel from their investment banking groups and Investor. As a result, research analysts employed by affiliates
of the Investor may hold views, make statements or investment recommendations and/or publish research reports with respect to the
Company or the transactions contemplated by the Transaction Documents that differ from the views of Investor.

 

    21 

     

    

 

Section 5.44. Emerging Growth Company Status.
From the time of the initial filing of the Company’s first registration statement with the Commission through the date hereof, the
Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging
Growth Company”).

 

ARTICLE VI 

ADDITIONAL COVENANTS 

 

The Company covenants with the Investor, and the Investor covenants
with the Company, as follows, which covenants of one party are for the benefit of the other party, during the Investment Period (and with
respect to the Company, for the period following the termination of this Agreement specified in Section 8.3 pursuant to and in accordance
with Section 8.3):

 

Section 6.1. Securities Compliance.
The Company shall notify the Commission and the Principal Market, if and as applicable, in accordance with their respective rules and
regulations, of the transactions contemplated by the Transaction Documents, and shall take all necessary action, undertake all proceedings
and obtain all registrations, permits, consents and approvals for the legal and valid issuance of the Shares to the Investor in accordance
with the terms of the Transaction Documents, as applicable.

 

Section 6.2. Reservation of Common
Stock. The Company has available and the Company shall reserve and keep available at all times, free of preemptive and other
similar rights of stockholders, the requisite aggregate number of authorized but unissued shares of Common Stock to enable the
Company to timely effect the issuance, sale and delivery of all Shares to be issued, sold and delivered in respect of each VWAP
Purchase effected under this Agreement, at least prior to the delivery by the Company to the Investor of the applicable VWAP
Purchase Notice in connection with such VWAP Purchase. Without limiting the generality of the foregoing, as of the Commencement
Date, the Company shall have reserved, out of its authorized and unissued Common Stock, a number of shares of Common Stock equal to
the Exchange Cap solely for the purpose of effecting VWAP Purchases under this Agreement. The number of shares of Common Stock so
reserved for the purpose of effecting VWAP Purchases under this Agreement may be increased from time to time by the Company from and
after the Commencement Date, and such number of reserved shares may be reduced from and after the Commencement Date only by the
number of Shares actually issued, sold and delivered to the Investor pursuant to any VWAP Purchase effected from and after the
Commencement Date pursuant to this Agreement.

 

    22 

     

    

 

Section 6.3. Registration and Listing.
The Company shall use its commercially reasonable efforts to cause the Common Stock to continue to be registered as a class of securities
under Sections 12(b) of the Exchange Act, and to comply with its reporting and filing obligations under the Exchange Act, and shall not
take any action or file any document (whether or not permitted by the Securities Act or the Exchange Act) to terminate or suspend such
registration or to terminate or suspend its reporting and filing obligations under the Exchange Act or Securities Act, except as permitted
herein. The Company shall use its commercially reasonable efforts to continue the listing and trading of its Common Stock and the listing
of the Shares purchased by the Investor hereunder on the Principal Market and to comply with the Company’s reporting, filing and
other obligations under the rules and regulations of the Principal Market. The Company shall not take any action which could be reasonably
expected to result in the delisting or suspension of the Common Stock on the Principal Market. If the Company receives any final and non-appealable
notice that the listing or quotation of the Common Stock on the Principal Market shall be terminated on a date certain, the Company shall
promptly (and in any case within 24 hours) notify the Investor of such fact in writing and shall use its commercially reasonable efforts
to cause the Common Stock to be listed or quoted on another Principal Market.

 

Section 6.4. Compliance with Laws.

 

(i) During the Investment Period,
the Company shall comply with applicable provisions of the Securities Act and the Exchange Act, including Regulation M thereunder,
applicable state securities or “Blue Sky” laws, and applicable listing rules of the Principal Market or Principal
Market, in connection with the transactions contemplated by this Agreement and the Registration Rights Agreement, except as would
not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Company to enter into and perform its
obligations under this Agreement in any material respect or for Investor to conduct resales of Shares under the Registration
Statement in any material respect.

 

(ii) The Investor shall comply with
all laws, rules, regulations and orders applicable to the performance by it of its obligations under this Agreement and its
investment in the Shares, except as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of
the Investor to enter into and perform its obligations under this Agreement in any material respect. Without limiting the foregoing,
the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act, including Regulation M
thereunder, and all applicable state securities or “Blue Sky” laws, in connection with the transactions contemplated by
this Agreement and the Registration Rights Agreement.

 

Section 6.5. Keeping of Records and Books
of Account; Due Diligence.

 

(i) The Investor and the Company
shall each maintain records showing the remaining Total Commitment, the remaining Aggregate Limit and the dates and VWAP Purchase
Share Amount for each VWAP Purchase.

 

    23 

     

    

 

(ii) Subject to the requirements of
Section 6.12, from time to time from and after the Closing Date, the Company shall make available for inspection and review by the
Investor during normal business hours and after reasonable notice, customary documentation reasonably requested by the Investor
and/or its appointed counsel or advisors to conduct due diligence; provided, however, that after the Closing Date, the
Investor’s continued due diligence shall not be a condition precedent to the Company’s right to deliver to the Investor
any VWAP Purchase Notice or the settlement thereof except to the extent expressly contemplated by this Agreement.

 

Section 6.6. No Frustration; No Variable
Rate Transactions.

 

(i) No Frustration.
The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of
which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its
obligations under the Transaction Documents to which it is a party, including, without limitation, the obligation of the Company to
deliver the Shares to the Investor in respect of a VWAP Purchase not later than the VWAP Purchase Share Delivery Date. For the
avoidance of doubt, nothing in this Section 6.6(i) shall in any way limit the Company’s right to terminate this Agreement in
accordance with Section 8.2 (subject in all cases to Section 8.3).

 

(ii) No Variable Rate
Transactions. The Company shall not effect or enter into an agreement to effect any issuance by the Company or any of its
Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction,
other than in connection with an Exempt Issuance. The Investor shall be entitled to seek injunctive relief against the Company and
its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without the
necessity of showing economic loss and without any bond or other security being required.

 

Section 6.7. Corporate Existence.
The Company shall take all steps necessary to preserve and continue the corporate existence of the Company; provided, however,
that, except as provided in Section 6.8, nothing in this Agreement shall be deemed to prohibit the Company from engaging in any Fundamental
Transaction with another Person. For the avoidance of doubt, nothing in this Section 6.7 shall in any way limit the Company’s right
to terminate this Agreement in accordance with Section 8.2 (subject in all cases to Section 8.3).

 

Section 6.8. Fundamental Transaction.
If a VWAP Purchase Notice has been delivered to the Investor and the transactions contemplated therein have not yet been fully settled
in accordance with the terms and conditions of this Agreement, the Company shall not effect any Fundamental Transaction until the expiration
of five (5) Trading Days following the date of full settlement thereof and the issuance to the Investor of all of the Shares issuable
pursuant to the VWAP Purchase to which such VWAP Purchase Notice relates.

 

    24 

     

    

 

Section 6.9. Selling Restrictions.

 

(i) Except as expressly set forth below, the Investor
covenants that from and after the Closing Date through and including the Trading Day next following the expiration or termination of this
Agreement as provided in Article VIII (the “Restricted Period”), none of the Investor any of its officers, or
any entity managed or controlled by the Investor (collectively, the “Restricted Persons” and each of the foregoing
is referred to herein as a “Restricted Person”) shall, directly or indirectly, (i) engage in any Short Sales
of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock, with respect
to each of clauses (i) and (ii) hereof, either for its own principal account or for the principal account of any other Restricted Person.
Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained herein shall (without implication that the
contrary would otherwise be true) prohibit any Restricted Person during the Restricted Period from: (1) selling “long” (as
defined under Rule 200 promulgated under Regulation SHO) the Shares; or (2) selling a number of shares of Common Stock equal to the number
of Shares that such Restricted Person is unconditionally obligated to purchase under a pending VWAP Purchase Notice but has not yet received
from the Company or the Transfer Agent pursuant to this Agreement, so long as (X) such Restricted Person (or the Broker-Dealer, as applicable)
delivers the Shares purchased pursuant to such VWAP Purchase Notice to the purchaser thereof or the applicable Broker-Dealer promptly
upon such Restricted Person’s receipt of such Shares from the Company in accordance with Section 3.2 of this Agreement and (Y) neither
the Company or the Transfer Agent shall have failed for any reason to deliver such Shares to the Investor or its Broker-Dealer so that
such Shares are received by the Investor as DWAC Shares on the applicable VWAP Purchase Share Delivery Date in accordance with Section
3.2 of this Agreement, including, without limitation, within the time period specified for receipt of such Shares by the Investor or its
Broker-Dealer as DWAC Shares from the Company or the Transfer Agent.

 

(ii) In addition to the foregoing,
in connection with any sale of Shares (including any sale permitted by paragraph (i) above), the Investor shall comply in all
respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements of the Securities
Act and the Exchange Act.

 

Section 6.10. Effective Registration Statement.
During the Investment Period, the Company shall use its commercially reasonable efforts to maintain the continuous effectiveness of the
Initial Registration Statement and each New Registration Statement filed with the Commission under the Securities Act for the applicable
Registration Period pursuant to and in accordance with the Registration Rights Agreement.

 

Section 6.11. Blue Sky. The
Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption for or to qualify the Shares
for sale by the Company to the Investor pursuant to the Transaction Documents, and at the request of the Investor, the subsequent
resale of Registrable Securities by the Investor, in each case, under applicable state securities or “Blue Sky” laws and
shall provide evidence of any such action so taken to the Investor from time to time following the Closing Date; provided, however,
that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any
jurisdiction where it would not otherwise be required to qualify but for this Section 6.11, (y) subject itself to general taxation
in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.

 

    25 

     

    

 

Section 6.12. Non-Public Information.
Neither the Company or any of its Subsidiaries, nor any of their respective directors, officers, employees or agents shall disclose any
material non-public information about the Company to the Investor during any VWAP Purchase Period, unless a simultaneous public announcement
thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the
Company or any of its Subsidiaries, or any of their respective directors, officers, employees and agents (as determined in the reasonable
good faith judgment of the Investor), (i) the Investor shall promptly provide written notice of such breach to the Company and (ii) after
such notice has been provided to the Company and, provided that the Company shall have failed to demonstrate to the Investor in writing
within 24 hours that such information does not constitute material, non-public information or the Company shall have failed to publicly
disclose such material, non-public information within 24 hours following demand therefor by the Investor, in addition to any other remedy
provided herein or in the other Transaction Documents, if the Investor is holding any Shares at the time of the disclosure of material,
non-public information, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement
or otherwise, of such material, non-public information without the prior approval by the Company, any of its Subsidiaries, or any of their
respective directors, officers, employees or agents. The Investor shall not have any liability to the Company, any of its Subsidiaries,
or any of their respective directors, officers, employees, stockholders or agents, for any such disclosure.

 

Section 6.13. Broker/Dealer. The
Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that it may purchase or otherwise acquire
from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be a DTC participant (collectively, the “Broker-Dealer”).
The Investor shall, from time to time, provide the Company and the Transfer Agent with all information regarding the Broker-Dealer reasonably
requested by the Company. The Investor shall be solely responsible for all fees and commissions of the Broker-Dealer (if any), which shall
not exceed customary brokerage fees and commissions and shall be responsible for designating only a DTC participant eligible to receive
DWAC Shares.

 

Section 6.14. Disclosure Schedule. 

 

(i) The Company may, from time to
time, update a disclosure schedule (the “Disclosure Schedule”) as may be required to satisfy the
conditions set forth in Section 7.2(i) and Section 7.3(i) (to the extent such condition set forth in Section 7.3(i) relates to the
condition in Section 7.2(i) as of a specific VWAP Purchase Condition Satisfaction Time). For purposes of this Section 6.14, any
disclosure made in a schedule to the Compliance Certificate shall be deemed to be an update of the Disclosure Schedule.
Notwithstanding anything in this Agreement to the contrary, no update to the Disclosure Schedule pursuant to this Section 6.14 shall
cure any breach of a representation or warranty of the Company contained in this Agreement and made prior to the update and shall
not affect any of the Investor’s rights or remedies with respect thereto.

 

    26 

     

    

 

(ii) Notwithstanding anything to
the contrary contained in the Disclosure Schedule or in this Agreement, the information and disclosure contained in any Schedule of
the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Schedule of the Disclosure
Schedule as though fully set forth in such Schedule for which applicability of such information and disclosure is readily apparent
on its face. The fact that any item of information is disclosed in the Disclosure Schedule shall not be construed to mean that such
information is required to be disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and the
thresholds (whether based on quantity, qualitative characterization, dollar amounts or otherwise) set forth herein shall not be used
as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this
Agreement.

 

Section 6.15. Delivery of Bring Down Opinions
and Compliance Certificates Upon Occurrence of Certain Events. Within three (3) Trading Days immediately following each time the
Company files (i) an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information
or a material amendment to the previously filed Form 10-K); (ii) a quarterly report on Form 10-Q under the Exchange Act; (iii) a current
report on Form 8-K containing amended financial information (other than information “furnished” pursuant to Items 2.02 or
7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain properties as
discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act; or (iv) the Initial
Registration Statement, any New Registration Statement, or any supplement or post-effective amendment thereto, and in any case, not more
than once per calendar quarter, the Company shall (1) deliver to the Investor a Compliance Certificate in the form attached hereto as
Exhibit B, dated such date, (2) cause to be furnished to the Investor an opinion from outside counsel to the Company substantially in
the form mutually agreed to by the Company and the Investor prior to the date of this Agreement (each such opinion, a “Bring-Down
Opinion”) and (3) cause to be furnished to the Investor a comfort letter from each and any independent registered public
accounting firm of the Company or its predecessors (in the case of a post-effective amendment, only if such amendment contains amended
or new financial information), modified, as necessary, to relate to such Registration Statement or post-effective amendment, or the Prospectus
contained therein as then amended or supplemented by such Prospectus Supplement, as applicable; provided that the Company shall not be
required to cause a comfort letter to be furnished to the Investor from Marcum with respect to the Company’s predecessors following
the events described in items (i) through (iii) above.

 

ARTICLE VII 

CONDITIONS TO CLOSING AND CONDITIONS TO THE
SALE AND 

PURCHASE OF THE SHARES 

 

Section 7.1. Conditions Precedent to Closing.
The Closing is subject to the satisfaction of each of the conditions set forth in this Section 7.1 on the Closing Date.

 

(i) Accuracy of the
Investor’s Representations and Warranties. The representations and warranties of the Investor contained in this
Agreement (a) that are not qualified by “materiality” shall be true and correct in all material respects as of the
Closing Date, except to the extent such representations and warranties are as of another date, in which case, such representations
and warranties shall be true and correct in all material respects as of such other date and (b) that are qualified by
 “materiality” shall be true and correct as of the Closing Date, except to the extent such representations and warranties
are as of another date, in which case, such representations and warranties shall be true and correct as of such other date.

 

    27 

     

    

 

(ii) Accuracy of the
Company’s Representations and Warranties. The representations and warranties of the Company contained in this
Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall be true and correct
in all material respects as of the Closing Date, except to the extent such representations and warranties are as of another date, in
which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b)
that are qualified by “materiality” or “Material Adverse Effect” shall be true and correct as of the Closing
Date, except to the extent such representations and warranties are as of another date, in which case, such representations and
warranties shall be true and correct as of such other date.

 

(iii) Issuance of Commitment Shares.
The Company shall deliver irrevocable instructions to its transfer agent to issue to the Investor, not later than 4:00 p.m. (New York
City time) on the second (2nd) Trading Day immediately following the Closing Date, a certificate or book-entry statement representing
the Commitment Shares in the name of the Investor or its designee (in which case such designee name shall have been provided to the Company
prior to the Closing Date), in consideration for the Investor’s execution and delivery of this Agreement. Such certificate or book-entry
statement shall be delivered to the Investor by overnight courier at its address set forth in Section 10.4 hereof. For the avoidance of
doubt, all of the Commitment Shares shall be fully earned as of the Closing Date regardless of whether any VWAP Purchases are made or
settled hereunder or any subsequent termination of this Agreement.

 

(iv) Closing
Deliverables. At the Closing, counterpart signature pages of this Agreement and the Registration Rights Agreement executed
by each of the parties hereto shall be delivered as provided in Section 2.2. Simultaneously with the execution and delivery of this
Agreement and the Registration Rights Agreement, the Investor’s counsel shall have (a) agreed to the forms of opinions to be
delivered to the Investor on the Commencement Date, (b) received the closing certificate from the Company, dated the Closing Date,
in the form of Exhibit B hereto , and (c) received a copy of the irrevocable instructions to the Company’s transfer
agent to be delivered to the Transfer Agent no later than the second (2nd) Trading Day immediately following the Closing Date,
regarding the issuance to the Investor or its designee of the certificate(s) or book-entry statement(s) representing the Commitment
Shares pursuant to and in accordance with Section 10.1(ii) hereof.

 

Section 7.2. Conditions Precedent to Commencement.
The right of the Company to commence delivering VWAP Purchase Notices under this Agreement, and the obligation of the Investor to accept
VWAP Purchase Notices delivered to the Investor by the Company under this Agreement, are subject to the initial satisfaction, at Commencement,
of each of the conditions set forth in this Section 7.2.

 

(i) Accuracy of the
Company’s Representations and Warranties. The representations and warranties of the Company contained in this
Agreement (a) that are not qualified by “materiality” or “Material Adverse Effect” shall have been true and
correct in all material respects when made and shall be true and correct in all material respects as of the Commencement Date with
the same force and effect as if made on such date, except to the extent such representations and warranties are as of another date,
in which case, such representations and warranties shall be true and correct in all material respects as of such other date and (b)
that are qualified by “materiality” or “Material Adverse Effect” shall have been true and correct when made
and shall be true and correct as of the Commencement Date with the same force and effect as if made on such date, except to the
extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true
and correct as of such other date.

 

    28 

     

    

 

(ii) Performance of the
Company. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by the
Company at or prior to the Commencement. The Company shall deliver to the Investor on the Commencement Date the compliance
certificate substantially in the form attached hereto as Exhibit C (the “Compliance
Certificate”).

 

(iii) Initial Registration
Statement Effective. The Initial Registration Statement covering the resale by the Investor of the Registrable Securities
included therein required to be filed by the Company with the Commission pursuant to Section 2(a) of the Registration Rights
Agreement shall have been declared effective under the Securities Act by the Commission, and the Investor shall be permitted to
utilize the Prospectus therein to resell (a) all of the Commitment Shares and (b) all of the Shares included in such Prospectus.

 

(iv) No Material
Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or
any other federal or state governmental authority for any additional information relating to the Initial Registration Statement, the
Prospectus contained therein or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial Registration
Statement, the Prospectus contained therein or any Prospectus Supplement thereto; (b) the issuance by the Commission or any other
federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or
prohibiting or suspending the use of the Prospectus contained therein or any Prospectus Supplement thereto, or of the suspension of
qualification or exemption from qualification of the Shares for offering or sale in any jurisdiction, or the initiation or
contemplated initiation of any proceeding for such purpose; or (c) the occurrence of any event or the existence of any condition or
state of facts, which makes any statement of a material fact made in the Initial Registration Statement, the Prospectus contained
therein or any Prospectus Supplement thereto untrue or which requires the making of any additions to or changes to the statements
then made in the Initial Registration Statement, the Prospectus contained therein or any Prospectus Supplement thereto in order to
state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made
therein (in the case of the Prospectus or any Prospectus Supplement, in the light of the circumstances under which they were made)
not misleading, or which requires an amendment to the Initial Registration Statement or a supplement to the Prospectus contained
therein or any Prospectus Supplement thereto to comply with the Securities Act or any other law. The Company shall have no Knowledge
of any event that could reasonably be expected to have the effect of causing the suspension of the effectiveness of the Initial
Registration Statement or the prohibition or suspension of the use of the Prospectus contained therein or any Prospectus Supplement
thereto in connection with the resale of the Registrable Shares by the Investor.

 

    29 

     

    

 

(v) Other Commission
Filings. The Current Report shall have been filed with the Commission as required pursuant to Section 2.3. The final
Prospectus included in the Initial Registration Statement shall have been filed with the Commission prior to Commencement in
accordance with Section 2.3 and the Registration Rights Agreement. All reports, schedules, registrations, forms, statements,
information and other documents required to have been filed by the Company with the Commission pursuant to the reporting
requirements of the Exchange Act, including all material required to have been filed pursuant to Section 13(a) or 15(d) of the
Exchange Act, prior to Commencement shall have been filed with the Commission.

 

(vi) No Suspension of Trading
in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the Commission, the
Principal Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company, which suspension
shall be terminated prior to the Commencement Date), the Company shall not have received any final and non-appealable notice that
the listing or quotation of the Common Stock on the Principal Market shall be terminated on a date certain (unless, prior to such
date certain, the Common Stock is listed or quoted on any other Principal Market), nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by DTC with
respect to the Common Stock that is continuing, the Company shall not have received any notice from DTC to the effect that a
suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or book-entry services by
DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or restriction, DTC shall
have notified the Company in writing that DTC has determined not to impose any such suspension or restriction).

 

(vii) Compliance with
Laws. The Company shall have complied with all applicable federal, state and local governmental laws, rules, regulations and
ordinances in connection with the execution, delivery and performance of this Agreement and the other Transaction Documents to which
it is a party and the consummation of the transactions contemplated hereby and thereby, including, without limitation, the Company
shall have obtained all permits and qualifications required by any applicable state securities or “Blue Sky” laws for
the offer and sale of the Shares by the Company to the Investor and the subsequent resale of the Registrable Securities by the
Investor (or shall have the availability of exemptions therefrom).

 

(viii) No Injunction.
No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or
endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would
materially modify or delay any of the transactions contemplated by the Transaction Documents.

 

(ix) No Proceedings or
Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have been
commenced, and no inquiry or investigation by any governmental authority shall have been commenced, against the Company or any
Subsidiary, or any of the officers, directors or Affiliates of the Company or any Subsidiary, seeking to restrain, prevent or change
the transactions contemplated by the Transaction Documents, or seeking material damages in connection with such transactions.

 

    30 

     

    

 

(x) Listing of
Shares. All of the Shares that have been and may be issued pursuant to this Agreement shall have been approved for listing
or quotation on the Principal Market as of the Commencement Date, subject only to notice of issuance.

 

(xi) No Material Adverse
Effect. No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall have occurred and be
continuing.

 

(xii) No Bankruptcy
Proceedings. No Person shall have commenced a proceeding against the Company pursuant to or within the meaning of any
Bankruptcy Law. The Company shall not have, pursuant to or within the meaning of any Bankruptcy Law, (a) commenced a voluntary case,
(b) consented to the entry of an order for relief against it in an involuntary case, (c) consented to the appointment of a Custodian
of the Company or for all or substantially all of its property, or (d) made a general assignment for the benefit of its creditors. A
court of competent jurisdiction shall not have entered an order or decree under any Bankruptcy Law that (I) is for relief against
the Company in an involuntary case, (II) appoints a Custodian of the Company or for all or substantially all of its property, or
(III) orders the liquidation of the Company or any of its Subsidiaries.

 

(xiii) Commitment Shares Issued as DWAC Shares.
The Company shall have caused the Company’s transfer agent to credit the Investor’s or its designee’s account at DTC
as DWAC Shares such number of shares of Common Stock equal to the number of Commitment Shares issued to the Investor pursuant to Section
10.1(ii) hereof, in accordance with Section 10.1(iv) hereof.

 

(xiv) Delivery of Commencement
Irrevocable Transfer Agent Instructions and Notice of Effectiveness. The Commencement Irrevocable Transfer Agent Instructions
shall have been executed by the Company and delivered to acknowledged in writing by the Company’s transfer agent, and the Notice
of Effectiveness relating to the Initial Registration Statement shall have been executed by the Company’s outside counsel and delivered
to the Transfer Agent, in each case directing the Transfer Agent to issue to the Investor or its designated Broker-Dealer all of the
Shares included in the Initial Registration Statement as DWAC Shares in accordance with this Agreement and the Registration Rights Agreement.

 

(xv) Reservation of
Shares. As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock a
number of shares of Common Stock equal to the Exchange Cap solely for the purpose of effecting VWAP Purchases under this
Agreement.

 

(xvi) Opinions of Company
Counsel. On the Commencement Date, the Investor shall have received the opinions and negative assurances from outside
counsel to the Company, dated the Commencement Date, in the forms mutually agreed to by the Company and the Investor prior to the
date of this Agreement.

 

    31 

     

    

 

(xvii) Comfort Letter of Accountant.
On the Commencement Date, the Investor shall have received from each of Ernst & Young and Marcum or a successor independent registered
public accounting firm for the Company, a letter dated the date of the filing of the Registration Statement addressed to the Investor,
in form and substance reasonably satisfactory to the Investor with respect to the audited and unaudited financial statements and certain
financial information contained in the Registration Statement and the Prospectus, and any Prospectus Supplement, except that the specific
date referred to therein for the carrying out of procedures shall be no more than three Business Days prior to the Commencement Date.

 

Section 7.3. Conditions Precedent to VWAP
Purchases after Commencement Date. The right of the Company to deliver VWAP Purchase Notices under this Agreement after the Commencement
Date, and the obligation of the Investor to accept VWAP Purchase Notices under this Agreement after the Commencement Date, are subject
to the satisfaction of each of the conditions set forth in this Section 7.3 at the applicable VWAP Purchase Commencement Time for the
VWAP Purchase to be effected pursuant to the applicable VWAP Purchase Notice timely delivered by the Company to the Investor in accordance
with this Agreement (each such time, a “VWAP Purchase Condition Satisfaction Time”).

 

(i) Satisfaction of Certain
Prior Conditions. Each of the conditions set forth in subsections (i), (ii), (vii) through (xiv), and (xvii) set forth in
Section 7.2 shall be satisfied at the applicable VWAP Purchase Condition Satisfaction Time after the Commencement Date (with the
terms “Commencement” and “Commencement Date” in the conditions set forth in subsections (i) and (ii) of
Section 7.2 replaced with “applicable VWAP Purchase Condition Satisfaction Time”); provided, however,
that the Company shall not be required to deliver the Compliance Certificate after the Commencement Date, except as provided in
Section 6.15 and Section 7.3(v).

 

(ii) Initial Registration
Statement Effective. The Initial Registration Statement covering the resale by the Investor of the Registrable Securities
included therein filed by the Company with the Commission pursuant to Section 2(a) of the Registration Rights Agreement, and any
post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date and prior to
the applicable VWAP Purchase Date pursuant to the Registration Rights Agreement, in each case shall have been declared effective
under the Securities Act by the Commission and shall remain effective for the applicable Registration Period (as defined in the
Registration Rights Agreement), and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement
thereto, to resell (a) all of the Commitment Shares and (b) all of the Shares included in the Initial Registration Statement, and
any post-effective amendment thereto, that have been issued and sold to the Investor hereunder pursuant to all VWAP Purchase Notices
delivered by the Company to the Investor prior to such applicable VWAP Purchase Date and (c) all of the Shares included in the
Initial Registration Statement, and any post-effective amendment thereto, that are issuable pursuant to the applicable VWAP Purchase
Notice delivered by the Company to the Investor with respect to a VWAP Purchase to be effected hereunder on such applicable VWAP
Purchase Date.

 

    32 

     

    

 

(iii) Any Required New
Registration Statement Effective. Any New Registration Statement covering the resale by the Investor of the Registrable
Securities included therein, and any post-effective amendment thereto, required to be filed by the Company with the Commission
pursuant to the Registration Rights Agreement after the Commencement Date and prior to the applicable VWAP Purchase Date, in each
case shall have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable
Registration Period, and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto,
to resell (a) all of the Commitment Shares (if any) included in the New Registration Statement, and any post-effective amendment
thereto, (n) all of the Shares included in such New Registration Statement, and any post-effective amendment thereto, that have been
issued and sold to the Investor hereunder pursuant to all VWAP Purchase Notices delivered by the Company to the Investor prior to
such applicable VWAP Purchase Date and (c) all of the Shares included in such new Registration Statement, and any post-effective
amendment thereto, that are issuable pursuant to the applicable VWAP Purchase Notice delivered by the Company to the Investor with
respect to a VWAP Purchase to be effected hereunder on such applicable VWAP Purchase Date.

 

(iv) Delivery of Subsequent Irrevocable
Transfer Agent Instructions and Notice of Effectiveness. With respect to any post-effective amendment to the Initial Registration
Statement, any New Registration Statement or any post-effective amendment to any New Registration Statement, in each case declared effective
by the Commission after the Commencement Date, the Company shall have delivered or caused to be delivered to the Transfer Agent (a) irrevocable
instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions executed by the Company and
acknowledged in writing by the Transfer Agent and (b) the Notice of Effectiveness, in each case modified as necessary to refer to such
Registration Statement or post-effective amendment and the Registrable Securities included therein, to issue the Registrable Securities
included therein as DWAC Shares in accordance with the terms of this Agreement and the Registration Rights Agreement.

 

(v) No Material
Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission or
any other federal or state governmental authority for any additional information relating to the Initial Registration Statement or
any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto, or for any amendment of or supplement to the Initial
Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment
thereto, or the Prospectus contained in any of the foregoing or any Prospectus Supplement thereto; (b) the issuance by the
Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial
Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment
thereto, or prohibiting or suspending the use of the Prospectus contained in any of the foregoing or any Prospectus Supplement
thereto, or of the suspension of qualification or exemption from qualification of the Shares for offering or sale in any
jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; or (c) the occurrence of any event or
the existence of any condition or state of facts, which makes any statement of a material fact made in the Initial Registration
Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the
Prospectus contained in any of the foregoing or any Prospectus Supplement thereto untrue or which requires the making of any
additions to or changes to the statements then made in the Initial Registration Statement or any post-effective amendment thereto,
any New Registration Statement or any post-effective amendment thereto, or the Prospectus contained in any of the foregoing or any
Prospectus Supplement thereto in order to state a material fact required by the Securities Act to be stated therein or necessary in
order to make the statements then made therein (in the case of the Prospectus or any Prospectus Supplement, in the light of the
circumstances under which they were made) not misleading, or which requires an amendment to the Initial Registration Statement or
any post-effective amendment thereto, any New Registration Statement or any post-effective amendment thereto, or the Prospectus
contained in any of the foregoing or any Prospectus Supplement thereto to comply with the Securities Act or any other law (other
than the transactions contemplated by the applicable VWAP Purchase Notice delivered by the Company to the Investor with respect to a
VWAP Purchase to be effected hereunder on such applicable VWAP Purchase Date and the settlement thereof). The Company shall have no
Knowledge of any event that could reasonably be expected to have the effect of causing the suspension of the effectiveness of the
Initial Registration Statement or any post-effective amendment thereto, any New Registration Statement or any post-effective
amendment thereto, or the prohibition or suspension of the use of the Prospectus contained in any of the foregoing or any Prospectus
Supplement thereto in connection with the resale of the Registrable Securities by the Investor.

 

    33 

     

    

 

(vi) Other Commission
Filings. The final Prospectus included in any post-effective amendment to the Initial Registration Statement, and any
Prospectus Supplement thereto, required to be filed by the Company with the Commission pursuant to Section 2.3 and the Registration
Rights Agreement after the Commencement Date and prior to the applicable VWAP Purchase Date, shall have been filed with the
Commission in accordance with Section 2.3 and the Registration Rights Agreement. The final Prospectus included in any New
Registration Statement and in any post-effective amendment thereto, and any Prospectus Supplement thereto, required to be filed by
the Company with the Commission pursuant to Section 2.3 and the Registration Rights Agreement after the Commencement Date and prior
to the applicable VWAP Purchase Date, shall have been filed with the Commission in accordance with Section 2.3 and the Registration
Rights Agreement. All reports, schedules, registrations, forms, statements, information and other documents required to have been
filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required
to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, after the Commencement Date and prior to the applicable
VWAP Purchase Date, shall have been filed with the Commission.

 

(vii) No Suspension of
Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the
Commission, the Principal Market or the FINRA (except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the applicable VWAP Purchase Date), the Company shall not have received any final and
non-appealable notice that the listing or quotation of the Common Stock on the Principal Market shall be terminated on a date
certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other Principal Market), nor shall there
have been imposed any suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or
book-entry services by DTC with respect to the Common Stock that is continuing, the Company shall not have received any notice from
DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common Stock, electronic trading or
book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension or
restriction, DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension or
restriction).

 

    34 

     

    

 

(viii) Certain
Limitations. The issuance and sale of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall not (a)
exceed the applicable VWAP Purchase Maximum Amount, (b) cause the Aggregate Limit or the Beneficial Ownership Limitation to be
exceeded, or (c) cause the Exchange Cap (to the extent applicable under Section 3.3) to be exceeded, unless in the case of this
clause (c), unless the Company’s stockholders have theretofore approved the issuance of Common Stock under this Agreement in
excess of the Exchange Cap in accordance with the applicable rules of the Principal Market.

 

(ix) Shares Authorized and
Delivered. All of the Shares issuable pursuant to the applicable VWAP Purchase Notice shall have been duly authorized by all
necessary corporate action of the Company. All Shares relating to all prior VWAP Purchase Notices required to have been received by
the Investor as DWAC Shares under this Agreement prior to the applicable VWAP Purchase Condition Satisfaction Time for the
applicable VWAP Purchase shall have been delivered to the Investor as DWAC Shares in accordance with this Agreement.

 

(x) Bring-Down Opinions of Company
Counsel, Bring-Down Comfort Letters and Compliance Certificates. The Investor shall have received (a) all Bring-Down Opinions
from outside counsel to the Company for which the Company was obligated to instruct its outside counsel to deliver to the Investor prior
to the applicable VWAP Purchase Condition Satisfaction Time for the applicable VWAP Purchase, (b) all Bring-Down comfort letters provided
by the Company’s auditors and delivered to the Investor prior to the applicable VWAP Purchase Condition Satisfaction Time for the
applicable VWAP Purchase and (c) all Compliance Certificates from the Company that the Company was obligated to deliver to the Investor
prior to the applicable VWAP Purchase Condition Satisfaction Time for the applicable VWAP Purchase, in each case in accordance with Section
6.15.

 

(xi) Material Non-Public
Information. Neither the Company nor, in the Investor’s sole discretion, the Investor, shall be in possession of any
material non-public information concerning the Company.

 

(xii) Payment of Expenses. The Company
shall be in compliance with its obligations pursuant to Section 10.1(i) of this Agreement and invoices for reimbursement the fees and
disbursements of legal counsel to the Investor shall not be more than 30 days in arrears.

 

    35 

     

    

 

ARTICLE VIII 

TERMINATION 

 

Section 8.1. Automatic Termination.
Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earliest to occur of (i) the first
day of the month next following the 36-month anniversary of the Effective Date of the Initial Registration Statement (it being hereby
acknowledged and agreed that such term may be extended by the parties hereto), (ii) the date on which the Investor shall have purchased
the Total Commitment worth of Shares pursuant to this Agreement, (iii) the date on which the Common Stock shall have failed to be listed
or quoted on the Principal Market or any other Principal Market, and (iv) the date on which, pursuant to or within the meaning of any
Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed
for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors.

 

Section 8.2. Other Termination.
Subject to Section 8.3, the Company may terminate this Agreement after the Commencement Date effective upon three (3) Trading
Days’ prior written notice to the Investor in accordance with Section 10.4; provided, however, that prior to
issuing any press release, or making any public statement or announcement, with respect to such termination, the Company shall
consult with the Investor and its counsel on the form and substance of such press release or other disclosure. Subject to Section
8.3, this Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such
mutual written consent unless otherwise provided in such written consent. Subject to Section 8.3, the Investor shall have the right
to terminate this Agreement effective upon three (3) Trading Days’ prior written notice to the Company, which notice shall be
made in accordance with Section 10.4, if: (a) any condition, occurrence, state of facts or event constituting a Material Adverse
Effect has occurred and is continuing; (b) a Fundamental Transaction shall have occurred; (c) the Company is in breach or default in
any material respect of any of its covenants and agreements the Registration Rights Agreement, and, if such breach or default is
capable of being cured, such breach or default is not cured within fifteen (15) Trading Days after notice of such breach or default
is delivered to the Company pursuant to Section 10.4 of this Agreement; (d) while a Registration Statement, or any post-effective
amendment thereto, is required to be maintained effective pursuant to the terms of the Registration Rights Agreement and the
Investor holds any Registrable Securities, the effectiveness of such Registration Statement, or any post-effective amendment
thereto, lapses for any reason (including, without limitation, the issuance of a stop order by the Commission) or such Registration
Statement or any post-effective amendment thereto, the Prospectus contained therein or any Prospectus Supplement thereto otherwise
becomes unavailable to the Investor for the resale of all of the Registrable Securities included therein in accordance with the
terms of the Registration Rights Agreement, and such lapse or unavailability continues for a period of forty-five (45) consecutive
Trading Days or for more than an aggregate of ninety (90) Trading Days in any three hundred and sixty-five (365)-day period, other
than due to acts of the Investor; (e) trading in the Common Stock on the Principal Market (or if the Common Stock is then listed on
an Principal Market, trading in the Common Stock on such Principal Market) shall have been suspended and such suspension continues
for a period of five (5) consecutive Trading Days; or (f) the Company is in material breach or default of any of its covenants and
agreements contained in this Agreement, and, if such breach or default is capable of being cured, such breach or default is not
cured within fifteen (15) Trading Days after notice of such breach or default is delivered to the Company pursuant to Section 10.4
of this Agreement. Unless notification thereof is required elsewhere in this Agreement (in which case such notification shall be
provided in accordance with such other provision), the Company shall promptly (but in no event later than twenty-four (24) hours)
notify the Investor (and, if required under applicable law, including, without limitation, Regulation FD promulgated by the
Commission, or under the applicable rules and regulations of the Principal Market (or if the Common Stock is then listed on an
Principal Market, under the applicable rules and regulations of such Principal Market), the Company shall publicly disclose such
information in accordance with Regulation FD and the applicable rules and regulations of the Principal Market (or such Principal
Market, as applicable)) upon becoming aware of any of the events set forth in the immediately preceding sentence.

 

    36 

     

    

 

Section 8.3. Effect of
Termination. In the event of termination by the Company or the Investor (other than by mutual termination) pursuant to
Section 8.2, written notice thereof shall forthwith be given to the other party as provided in Section 10.4 and the transactions
contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as
provided in Section 8.1 or Section 8.2, this Agreement shall become void and of no further force and effect, except that (i) the
provisions of Article V (Representations, Warranties and Covenants of the Company), Article IX (Indemnification), Article X
(Miscellaneous) and this Article VIII (Termination) shall remain in full force and effect indefinitely notwithstanding such
termination, and, (ii) so long as the Investor owns any Shares, the covenants and agreements of the Company contained in Article VI
(Additional Covenants) shall remain in full force and notwithstanding such termination for a period of thirty (30) days following
such termination. Notwithstanding anything in this Agreement to the contrary, no termination of this Agreement by any party shall
(i) become effective prior to the second (2nd) Trading Day immediately following the date on which the purchase of Shares by the
Investor pursuant to any pending VWAP Purchase has been fully settled, including, without limitation, the delivery by the Company to
the Investor of all Shares purchased by the Investor pursuant to such pending VWAP Purchase as DWAC Shares on the applicable VWAP
Purchase Share Delivery Date therefor, and the delivery by the Investor to the Company of the aggregate VWAP Purchase Price payable
by the Investor for such Shares, in each case in accordance with the settlement procedures set forth in Section 3.2 of this
Agreement (it being hereby acknowledged and agreed that no termination of this Agreement shall limit, alter, modify, change or
otherwise affect any of the Company’s or the Investor’s rights or obligations under the Transaction Documents with
respect to any pending VWAP Purchase that has not fully settled, and that the parties shall fully perform their respective
obligations with respect to any such pending VWAP Purchase under the Transaction Documents), (ii) limit, alter, modify, change or
otherwise affect the Company’s or the Investor’s rights or obligations under the Registration Rights Agreement, all of
which shall survive any such termination, or (iii) affect any Commitment Shares issued or issuable or the to the Investor pursuant
to Section 10.1(ii), it being hereby acknowledged and agreed that the entire amount of the Commitment Shares Fee shall be fully
earned by the Investor and shall be non-refundable as of the Closing Date, regardless of whether any VWAP Purchases are made or
settled hereunder or any subsequent termination of this Agreement. Nothing in this Section 8.3 shall be deemed to release the
Company or the Investor from any liability for any breach or default under this Agreement, the Registration Rights Agreement or any
of the other Transaction Documents to which it is a party, or to impair the rights of the Company and the Investor to compel
specific performance by the other party of its obligations under this Agreement, the Registration Rights Agreement or any of the
other Transaction Documents to which it is a party.

 

    37 

     

    

 

 

ARTICLE IX 

INDEMNIFICATION 

 

Section 9.1. Indemnification of
Investor. In consideration of the Investor’s execution and delivery of this Agreement and acquiring the Shares
hereunder and in addition to all of the Company’s other obligations under the Transaction Documents to which it is a party,
subject to the provisions of this Section 9.1, the Company shall indemnify and hold harmless the Investor, its affiliates, each of
their respective directors, officers, shareholders, members, partners, employees, representatives and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title), each
Person, if any, who controls the Investor (within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange
Act), and the respective directors, officers, shareholders, members, partners, employees, representatives and agents (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other
title) of such controlling Persons (each, an “Investor Party”), from and against all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses (including all judgments, amounts paid in settlement, court costs,
reasonable attorneys’ fees and costs of defense and investigation) (collectively, “Damages”) that
any Investor Party may suffer or incur (a) as a result of, relating to or arising out of or based upon any untrue statement or
alleged untrue statement of a material fact contained in any Commission Document (or any amendment thereto), or the omission or
alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not
misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any Commission
Document, or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided, however, that this indemnity in (a)
shall not apply to any loss, liability, claim, damage or expense to the extent arising out of an untrue statement or omission, or
alleged untrue statement or omission in a Commission Document, made in reliance upon and in conformity with information furnished in
writing to the Company by the Investor for the Investor expressly for use in connection with the preparation of the Registration
Statement, Prospectus or Prospectus Supplement or any such amendment thereof or supplement thereto (it being hereby acknowledged and
agreed that the written information set forth on Exhibit C to the Registration Rights Agreement is the only written
information furnished to the Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or
Prospectus Supplement), (b) to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or
proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission; provided that any such settlement is effected with the written
consent of the Company, which consent shall not unreasonably be delayed, conditioned or withheld, (c) in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or any
claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or not
a party), to the extent that any such expense is not paid under (a) or (b) above, (d) as a result of, relating to or
arising out of any breach by the Company of its representations, warranties, covenants or agreements under this Agreement, or (e) as
a result of, relating to or arising out of any other action, suit, claim or proceeding against an Investor Party arising out of or
otherwise in connection with the Transaction Documents (except solely to the extent in the case of this subsection (e), to the
extent any Damage is determined by a court of competent jurisdiction, not subject to further appeal, to have resulted primarily and
directly from the bad faith or gross negligence, or willful misconduct of such Investor Party).

 

    38 

     

    

 

The Company shall reimburse any Investor Party promptly upon demand
(with accompanying presentation of documentary evidence) for all legal and other costs and expenses reasonably incurred by such Investor
Party in connection with (i) any action, suit, claim or proceeding, whether at law or in equity, to enforce compliance by the Company
with any provision of the Transaction Documents or (ii) any other any action, suit, claim or proceeding, whether at law or in equity,
with respect to which it is entitled to indemnification under this Section 9.1, provided that the Investor shall promptly reimburse the
Company for all such legal and other costs and expenses to the extent a court of competent jurisdiction determines in a final judgment
that any Investor Party was not entitled to such reimbursement.

 

To the extent that the foregoing undertakings by the Company set forth
in this Section 9.1 may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction
of each of the Damages which is permissible under applicable law, provided that in no event shall the Investor be obligated to contribute
any amount in excess of the fees it actually receives pursuant to this Agreement.

 

Section 9.2. Indemnification Procedures.

 

(a) Promptly after an Investor Party
receives notice of a claim or the commencement of an action for which the Investor Party intends to seek indemnification under
Section 9.1, the Investor Party will notify the Company in writing of the claim or commencement of the action, suit or proceeding; provided, however,
that failure to notify the Company will not relieve the Company from liability under Section 9.1, unless and solely to the extent it
has been materially prejudiced by the failure to give such notice as evidenced by the forfeiture of by the Company of substantive
rights or defenses. The Company will be entitled to participate in the defense of any claim, action, suit or proceeding as to which
indemnification is being sought, and if the Company acknowledges in writing the obligation to indemnify the Investor Party against
whom the claim or action is brought, the Company may (but will not be required to) assume the defense against the claim, action,
suit or proceeding with counsel satisfactory to it. After the Company notifies the Investor Party that the Company wishes to assume
the defense of a claim, action, suit or proceeding, the Company will not be liable for any further legal or other expenses incurred
by the Investor Party in connection with the defense against the claim, action, suit or proceeding unless (1) the employment of
counsel by the Investor Party has been authorized in writing by the Company, (2) the Investor Party has reasonably concluded (based
on advice of counsel) that there may be legal defenses available to it or another Investor Party that are different from or in
addition to those available to the Company, (3) a conflict or potential conflict exists (based on advice of counsel to the Investor
Party) between an Investor Party and the Company (in which case the Company will not have the right to direct the defense of such
action on behalf of the indemnified party) or (4) the Company has not in fact employed counsel to assume the defense of such action
or counsel reasonably satisfactory to the indemnified party, in each case, within a reasonable time after receiving notice of the
commencement of the action; in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the
expense of the Company. It is understood that the Company shall not, in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local
counsel) admitted to practice in such jurisdiction at any one time for all such similarly situated Investor Parties. The Company
will not be liable for any settlement of any action effected without its prior written consent, which consent shall not be
unreasonably withheld, delayed or conditioned. The Company shall not, without the prior written consent of each indemnified party,
settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to
the matters contemplated by this section (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent (1) includes an express and unconditional release of each indemnified party, in form and substance reasonably
satisfactory to such indemnified party, from all liability arising out of such litigation, investigation, proceeding or claim and
(2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified
party.

 

    39 

     

    

 

(b) In order to provide for just and
equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Article IX for
any reason is held to be unavailable or insufficient to hold an Investor Party harmless, the Company and the Investor Party will
contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses
reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted)
to which the Company and the Investor Party may be subject in such proportion as shall be appropriate to reflect the relative
benefits received by the Company on the one hand and the Investor on the other hand. The relative benefits received by the Company
on the one hand and the Investor Party on the other hand shall be deemed to be in the same proportion as the total net proceeds from
the aggregate of all VWAP Purchase Amounts (before deducting expenses) received by the Company bear to the total compensation
received by the Investor from the Company pursuant to this Agreement. If, but only if, the allocation provided by the foregoing
sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to
reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one
hand, and the Investor Party, on the other hand, with respect to the statements or omission that resulted in such loss, claim,
liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to
such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company
or the Investor Party, the intent of the parties and their relative knowledge, access to information and opportunity to correct or
prevent such statement or omission. The Company and the Investor Party agree that it would not be just and equitable if
contributions pursuant to this Section 9.2(b) were to be determined by pro rata allocation or by any other method of allocation that
does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a
result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 9.2(b)
shall be deemed to include, for the purpose of this Section 9.2(b), any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim to the extent consistent with Section
9.2(a) hereof. Notwithstanding the foregoing provisions of this Section 9.2(b), the Investor shall not be required to contribute any
amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation. For purposes of this Section 9.2(b), any person who controls a party to this Agreement within the
meaning of the Securities Act, any affiliates of the Investor Party and any officers, directors, partners, employees or agents of
the Investor Party or any of its affiliates, will have the same rights to contribution as that party, and each director of the
Company and each officer of the Company who signed the Registration Statement will have the same rights to contribution as the
Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9(b), will
notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or
parties from whom contribution may be sought from any other obligation it or they may have under this Section 9(b) except to the
extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from
whom contribution is sought. No party will be liable for contribution with respect to any action or claim settled without its
written consent if such consent is required pursuant to Section 9.2(a) hereof.

 

The remedies provided for in this Article IX are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any Investor Party at law or in equity.

 

    40 

     

    

 

ARTICLE X 

MISCELLANEOUS 

 

Section 10.1. Certain Fees and Expenses;
Commencement Irrevocable Transfer Agent Instructions. 

 

(i) Certain Fees and
Expenses. Each party shall bear its own fees and expenses related to the transactions contemplated by this Agreement except
that the Company will reimburse the fees and disbursements of legal counsel to the Investor in an amount not to exceed $75,000 in
connection with the entry into this Agreement and $25,000 per fiscal quarter in connection with the Investor’s ongoing due
diligence and review of deliverables subject to Section 6.15. The Company shall pay all U.S. federal, state and local stamp and
other similar transfer and other taxes and duties levied in connection with issuance of the Shares pursuant hereto.

(ii) Commitment Shares. In
consideration for the Investor’s execution and delivery of this Agreement concurrently with the execution and delivery of this
Agreement on the Closing Date, the Company shall deliver irrevocable instructions to its transfer agent to issue to the Investor,
not later than 4:00 p.m. (New York City time) on the Trading Day immediately following the Closing Date, one or more certificate(s)
or book-entry statement(s) representing the Commitment Shares in the name of the Investor or its designee (in which case such
designee name shall have been provided to the Company prior to the Closing Date). Such certificate or book-entry statement shall be
delivered to the Investor by overnight courier at its address set forth in Section 10.4. Upon issuance pursuant to this Section
10.1(ii), the Commitment Shares shall constitute “restricted securities” as such term is defined in Rule 144(a)(3) under
the Securities Act and, subject to the provisions of subsection (iv) of this Section 10.1, the certificate or book-entry statement
representing the Commitment Shares shall bear the restrictive legend set forth below in subsection (iii) of this Section 10.1. The
Commitment Shares shall constitute Registrable Securities and shall be included in the Initial Registration Statement and any
post-effective amendment thereto, and the Prospectus included therein, and, if necessary to register the resale thereof by the
Investor under the Securities Act, in any New Registration Statement and any post-effective amendment thereto, and the Prospectus
included therein, in each case in accordance with this Agreement and the Registration Rights Agreement. For the avoidance of doubt,
all of the Commitment Shares and the entire amount shall be fully earned by the Investor and shall be non-refundable as of the
Closing Date, regardless of whether any VWAP Purchases are made or settled hereunder or any subsequent termination of this
Agreement.

 

    41 

     

    

 

(iii) Legends. The
certificate(s) or book-entry statement(s) representing the Commitment Shares issued prior to the Effective Date of the Initial
Registration Statement, except as set forth below, shall bear a restrictive legend in substantially the following form (and stop
transfer instructions may be placed against transfer of the Commitment Shares):

 

THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN
ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT
TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.

 

Notwithstanding the foregoing and
for the avoidance of doubt, all Shares to be issued in respect of any VWAP Purchase Notice delivered to the Investor pursuant to
this Agreement shall be issued to the Investor in accordance with Section 3.2 by crediting the Investor’s or its
designees’ account at DTC as DWAC Shares, and the Company shall not take any action or give instructions to any transfer agent
of the Company otherwise.

 

(iv) Irrevocable Transfer Agent
Instructions; Notice of Effectiveness. On the earlier of (a) the Commencement Date and (b) such time that the Investor shall
request, provided all conditions of Rule 144 are met, the Company shall, no later than one (1) Trading Day following the delivery by
the Investor to the Company or its transfer agent of one or more legended certificates or book-entry statements representing the
Commitment Shares issued to the Investor pursuant to Section 10.1(ii) (which certificates or book-entry statements the Investor
shall promptly deliver on or prior to the first to occur of the events described in clauses (a) and (b) of this sentence), cause the
Company’s transfer agent to credit the Investor’s or its designee’s account at DTC as DWAC Shares such number of
shares of Common Stock equal to the number of Commitment Shares issued to the Investor pursuant to Section 10.1(ii). The Company
shall take all actions to carry out the intent and accomplish the purposes of the immediately preceding sentence, including, without
limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to its transfer agent, and any
successor transfer agent of the Company, as may be requested from time to time by the Investor or necessary or desirable to carry
out the intent and accomplish the purposes of the immediately preceding sentence. On the Effective Date of the Initial Registration
Statement and prior to Commencement, the Company shall deliver or cause to be delivered to its Transfer Agent (and thereafter, shall
deliver or cause to be delivered to any subsequent transfer agent of the Company), (i) irrevocable instructions executed by the
Company and acknowledged in writing by the Company’s transfer agent (the “Commencement Irrevocable Transfer Agent
Instructions”) and (ii) the notice of effectiveness in the form attached as an exhibit to the Registration Rights
Agreement (the “Notice of Effectiveness”) relating to the Initial Registration Statement executed by the
Company’s outside counsel, in each case directing the Transfer Agent to issue to the Investor or its designated Broker-Dealer
at which the account or accounts to be credited with Commitment Shares and the Shares being purchased by Investor are maintained any
Registrable Securities included in the Initial Registration Statement as DWAC Shares, if and when such Registrable Securities are
issued in accordance with this Agreement and the Registration Rights Agreement. With respect to any post-effective amendment to the
Initial Registration Statement, any New Registration Statement or any post-effective amendment to any New Registration Statement, in
each case declared effective by the Commission after the Commencement Date, the Company shall deliver or cause to be delivered to
its Transfer Agent (and thereafter, shall deliver or cause to be delivered to any subsequent transfer agent of the Company) (i)
irrevocable instructions in the form substantially similar to the Commencement Irrevocable Transfer Agent Instructions executed by
the Company and acknowledged in writing by the Transfer Agent and (ii) the Notice of Effectiveness, in each case modified as
necessary to refer to such Registration Statement or post-effective amendment and the Registrable Securities included therein, to
issue the Registrable Securities included therein as DWAC Shares in accordance with the terms of this Agreement and the Registration
Rights Agreement. For the avoidance of doubt, all Shares and Commitment Shares to be issued in respect of any VWAP Purchase Notice
delivered to the Investor pursuant to this Agreement shall be issued to the Investor in accordance with Section 3.2 by crediting the
Investor’s account at DTC as DWAC Shares, and the Company shall not take any action or give instructions to any transfer agent
of the Company otherwise. The Company represents and warrants to the Investor that, while this Agreement is effective, no
instruction other than those referred to in this Section 10.1(iii) will be given by the Company to its Transfer Agent, or any
successor transfer agent of the Company, with respect to the Shares and the Commitment Shares from and after Commencement, and the
Registrable Securities covered by the Initial Registration Statement or any post-effective amendment thereof, or any New
Registration Statement or post-effective amendment thereof, as applicable, shall otherwise be freely transferable on the books and
records of the Company and no stop transfer instructions shall be maintained against the transfer thereof. The Company agrees that
if the Company fails to fully comply with the provisions of this Section 10.1(iii) within three (3) Trading Days after the date on
which the Investor has provided any deliverables that the Investor may be required to provide to the Company or its Transfer Agent
(if any), the Company shall, at the Investor’s written instruction, purchase from the Investor all shares of Common Stock
purchased or acquired by the Investor pursuant to this Agreement that contain the restrictive legend referred to in Section
10.1(iii) hereof or any similar restrictive legend or that have any stop transfer orders maintained that prohibit or impede the
transfer thereof in any respect at the greater of (i) the purchase price paid by the Investor for such shares of Common Stock (as
applicable) and (ii) the Closing Sale Price of the Common Stock on the date of the Investor’s written instruction.

 

    42 

     

    

 

Section 10.2. Specific Enforcement, Consent
to Jurisdiction, Waiver of Jury Trial.

 

(i) The Company and the Investor
acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either party shall be
entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to
enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other
security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

(ii) Each of the Company and the
Investor (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of the United States sitting
in the State of New York for the purposes of any suit, action or proceeding arising out of or relating to this Agreement, and (b)
hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit,
action or proceeding is improper. Each of the Company and the Investor consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 10.2 shall affect
or limit any right to serve process in any other manner permitted by law.

 

(iii) EACH OF THE COMPANY AND THE
INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY
LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY
OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY
OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE ENTERED INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.2.

 

    43 

     

    

 

Section 10.3. Entire Agreement.
The Transaction Documents set forth the entire agreement and understanding of the parties with respect to the subject matter hereof
and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written,
with respect to such matters. There are no promises, undertakings, representations or warranties by either party relative to subject
matter hereof not expressly set forth in the Transaction Documents. All exhibits to this Agreement are hereby incorporated by
reference in, and made a part of, this Agreement as if set forth in full herein.

 

Section 10.4. Notices. Any notice,
demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective
(a) upon hand delivery or electronic mail delivery at the address or number designated below (if delivered on a business day during normal
business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business
day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
The address for such communications shall be:

 

If to the Company:

 

Wejo Group Limited

Canon’s Court, 22 Victoria Street
Hamilton, Bermuda

Telephone Number: +44-8002-343065

Email: Mina.Bhama@wejo.com

Attention:

Mina Bhama

General Counsel and Corporate Secretary

 

With a copy (which shall not constitute
notice) to:

 

Weil, Gotshal & Manges LLP

767 5th Avenue New York, NY
10153

Telephone Number: 212-310-8000

Email: corey.chivers@weil.com

Attention: CF Principal Investments LLC

 

If to the Investor:

 

CF Principal Investments LLC

499 Park Avenue

New York, NY 10022

 

and:

 

CF Principal Investments LLC 499 Park
Avenue

New York, NY 10022

Attention: General Counsel

Facsimile: (212) 829-4708

Email: #lebal-IBD@cantor.com

 

With a copy (which shall not constitute
notice) to:

 

King & Spalding LLP

1185 6th Avenue, Floor 34,
New York, NY 10036

Telephone Number: 212-556-2100

Email: kmanz@kslaw.com

 

Either party hereto may
from time to time change its address for notices by giving at least five (5) days’ advance written notice of such changed address
to the other party hereto.

 

    44 

     

    

 

Section 10.5. Waivers. No provision
of this Agreement may be waived by the parties from and after the date that is one (1) Trading Day immediately preceding the filing of
the Initial Registration Statement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement
may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. No failure or
delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise
of any such power, right or privilege preclude other or further exercises thereof or of any other right, power or privilege.

 

Section 10.6. Amendments. No provision
of this Agreement may be amended by the parties from and after the date that is one (1) Trading Day immediately preceding the filing of
the Initial Registration Statement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement
may be amended other than by a written instrument signed by both parties hereto.

 

Section 10.7. Headings. The article,
section and subsection headings in this Agreement are for convenience only and shall not constitute a part of this Agreement for any other
purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context clearly indicates otherwise, each
pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,”
 “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without
limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this
entire Agreement instead of just the provision in which they are found.

 

Section 10.8. Construction. The parties
agree that each of them and their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore,
the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed
in the interpretation of the Transaction Documents. In addition, each and every reference to share prices (including the Threshold Price)
and number of shares of Common Stock in any Transaction Document shall, in all cases, be subject to adjustment for any stock splits, stock
combinations, stock dividends, recapitalizations, reorganizations and other similar transactions that occur on or after the date of this
Agreement. Any reference in this Agreement to “Dollars” or “$” shall mean the lawful currency of the United States
of America. Any references to “Section” or “Article” in this Agreement shall, unless otherwise expressly stated
herein, refer to the applicable Section or Article of this Agreement.

 

Section 10.9. Binding Effect. This
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors. Neither the Company nor
the Investor may assign this Agreement or any of their respective rights or obligations hereunder to any Person.

 

Section 10.10. No Third-Party Beneficiaries.
Except as expressly provided in Article IX, this Agreement is intended only for the benefit of the parties hereto and their respective
successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

    45 

     

    

 

Section 10.11. Governing Law. This
Agreement shall be governed by and construed in accordance with the internal procedural and substantive laws of the State of New York,
without giving effect to the choice of law provisions of such state that would cause the application of the laws of any other jurisdiction.

 

Section 10.12. Survival. The representations,
warranties, covenants and agreements of the Company and the Investor contained in this Agreement shall survive the execution and delivery
hereof until the termination of this Agreement; provided, however, that (i) the provisions of Article VIII (Termination),
Article IX (Indemnification) and this Article X (Miscellaneous) shall remain in full force and effect indefinitely notwithstanding such
termination, and, (ii) so long as the Investor owns any Shares, the covenants and agreements of the Company and the Investor contained
in Article VI (Additional Covenants), shall remain in full force and effect notwithstanding such termination for a period of thirty (30)
days following such termination.

 

Section 10.13. Counterparts. This
Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature
or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding
upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

Section 10.14. Publicity. The Company
shall afford the Investor and its counsel with a reasonable opportunity to review and comment upon, shall consult with the Investor and
its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any
press release, Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor, its purchases
hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, prior to the issuance, filing or public
disclosure thereof. For the avoidance of doubt, the Company shall not be required to submit for review any such disclosure (i) contained
in periodic reports filed with the Commission under the Exchange Act if it shall have previously provided the same disclosure to the Investor
or its counsel for review in connection with a previous filing or (ii) any Prospectus Supplement if it contains disclosure that does not
reference the Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby.

 

Section 10.15. Severability. The
provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or
more of the provisions or part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision
of this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part
of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent
possible.

 

Section 10.16. Further Assurances.
From and after the Closing Date, upon the request of the Investor or the Company, each of the Company and the Investor shall execute and
deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate
fully the intent and purposes of this Agreement.

 

    46 

     

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed by their respective authorized officer as of the date first above written.

 

	 	Wejo Group Limited

 

	 	By:	/s/ John Maxwell

	 	Name:	John Maxwell
	 	Title:	Chief Financial Officer

 

	 	CF Principal Investments LLC

 

	 	By:	/s/ Mark Kaplan

	 	Name:	Mark Kaplan
	 	Title:	 

 

[Signature Page to Equity Line Agreement]

 

     

     

    

 

ANNEX I TO THE

COMMON STOCK PURCHASE AGREEMENT 

DEFINITIONS 

 

“Affiliate” means any
Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with a
Person, as such terms are used in and construed under Rule 144.

 

“Bankruptcy Law” means
Title 11, U.S. Code, or any similar U.S. federal or state law for the relief of debtors.

 

“Bloomberg” means Bloomberg,
L.P.

 

“Business Data” means
all business information and data, including Personal Information (whether of employees, contractors, consultants, customers, consumers,
or other persons and whether in electronic or any other form or medium) that is accessed, collected, used, stored, shared, distributed,
transferred, disclosed, destroyed, disposed of or otherwise processed by any of the Business Systems or otherwise in the course of the
conduct of the business of the Company and its Subsidiaries.

 

“Business Systems” means
all Software, computer hardware (whether general or special purpose), electronic data processors, databases, communications, telecommunications,
networks, interfaces, platforms, servers, peripherals, and computer systems, including any outsourced systems and processes, that are
owned or used in the conduct of the business of the Company and its Subsidiaries.

 

“Closing Date” means
the date of this Agreement.

 

“Closing Sale Price”
means, for the Common Stock as of any date, the last closing trade price for the Common Stock on the Principal Market, as reported by
Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price for
the Common Stock, then the last trade price for the Common Stock prior to 4:00 p.m., New York City time, as reported by Bloomberg. All
such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other
similar transactions during such period.

 

“Commencement Irrevocable Transfer
Agent Instructions” shall have the meaning assigned to such term in Section 10.1(iv).

 

“Commission” means the
U.S. Securities and Exchange Commission or any successor entity.

 

     

     

    

 

“Commission
Documents” shall mean (1) the Company’s registration statement on Form S-4 initially filed with the Commission
on July 16, 2021, including any related prospectus or prospectuses, for the registration of the Common Stock to be issued pursuant
to the agreement and plan of merger by and among the and Virtuoso Acquisition Corp., on file with the Commission at the time such
registration statement became effective, including the financial statements, schedules, exhibits and all other documents filed as a
part thereof or incorporated therein and all information deemed to be a part thereof as of the effective date of such registration
statement under the Securities Act (the “Company Form S-4 Registration Statement”), (2) the
Company’s registration statement on Form S-1 (File No. 333-261746) initially filed with the Commission on December 17, 2021,
including any related prospectus or prospectuses (the “Company Form S-1 Registration Statement”), (3) the
proxy statement/prospectus, dated October 22, 2021, including all documents incorporated or deemed incorporated therein by
reference, included in the Registration Statement, as it may be supplemented, in the form in which such proxy statement/prospectus
has most recently been filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Company Merger
Proxy Statement/Prospectus”), (4) the Company’s 10-Q, initially filed on November 26, 2021, and the
Company’s amended 10-Q/A, dated December 17, 2021, (5) all reports, schedules, registrations, forms, statements, information
and other documents filed with or furnished to the Commission by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the
Exchange Act since October 22, 2021, including, without limitation, the Current Report, (6) each Registration Statement, as the same
may be amended from time to time, the Prospectus contained therein and each Prospectus Supplement thereto and (7) all information
contained in such filings and all documents and disclosures that have been and heretofore shall be incorporated by reference
therein.

 

“Commitment Shares” means
715,991 shares of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock which, concurrently with the execution
and delivery of this Agreement on the Closing Date, the Company has caused its transfer agent to issue and deliver to the Investor not
later than 4:00 p.m. (New York City time) on the Trading Day immediately following the Closing Date.

 

“Common Stock Equivalents”
means any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Contract” means any
written or oral legally binding contract, agreement, understanding, arrangement, subcontract, loan or credit agreement, note, bond, indenture,
mortgage, purchase order, deed of trust, lease, sublease, instrument, or other legally binding commitment, obligation or undertaking.

 

“Custodian” shall mean
any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

“DTC” means The Depository
Trust Company, a subsidiary of The Depository Trust & Clearing Corporation, or any successor thereto.

 

“DWAC Shares” means
shares of Common Stock issued pursuant to this Agreement that are (i) issued in electronic form, (ii) freely tradable and
transferable and without restriction on resale and without stop transfer instructions maintained against the transfer thereof and
(iii) timely credited by the Company to the Investor’s or its designated Broker-Dealer at which the account or accounts to be
credited with the Shares being purchased by Investor are maintained specified DWAC account with DTC under its Fast Automated
Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.

 

     

     

    

 

“EDGAR” means the Commission’s
Electronic Data Gathering, Analysis and Retrieval System.

 

“Effective Date” means,
with respect to the Initial Registration Statement filed pursuant to Section 2(a) of the Registration Rights Agreement (or any post-effective
amendment thereto) or any New Registration Statement filed pursuant to Section 2(c) of the Registration Rights Agreement (or any post-effective
amendment thereto), as applicable, the date on which the Initial Registration Statement (or any post-effective amendment thereto) or any
New Registration Statement (or any post-effective amendment thereto) is declared effective by the Commission.

 

“Encumbrance” means any
security interest, pledge, hypothecation, mortgage, lien or encumbrance, covenant, condition, restriction, easement, charge, right of
first refusal or first offer, or other restriction on title or transfer of any nature whatsoever.

 

“Environmental Law” means
any statute, law, ordinance, regulation, rule or code concerning or relating to: (i) the protection of the environment or natural resources
or, as such relates to exposure to Hazardous Materials, human health and safety (including workplace and industrial hygiene); (ii) the
presence, Release, generation, use, management, handling, transportation, treatment, storage or disposal of Hazardous Materials; (iii)
noise or odor including, without limitation, in the United States, the Comprehensive Environmental Response, Compensation, and Liability
Act, 42 U.S.C. § 9601, et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, 42
U.S.C. 6901, et seq.; the Toxic Substances Control Act, 15 U.S.C. 2601, et seq.; the Federal Water Pollution Control Act, 33 U.S.C. 1251,
et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. 5101; the Safe Drinking Water Act, 42 U.S.C. 300f, et seq.; as it relates
to exposure to Hazardous Materials, the Occupational Safety and Health Act, 29 U.S.C. 651, et seq.; the Emergency Planning and Community
Right to Know Act of 1986, 42 U.S.C. 11001, et seq.; the Atomic Energy Act, 42 U.S.C. 2014, et seq.; the Endangered Species Act, 16 U.S.C.
1531, et seq.; the Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. 136, et seq.; the Clean Air Act, 42 U.S.C. 7401, et seq.;
and the state and local analogues of each of the foregoing federal statutes.

 

“Environmental Permit”
means any Permit, approval, identification number, registration, exemption or license required pursuant to any applicable Environmental
Law.

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

     

     

    

 

“Exempt Issuance”
means the issuance of (a) Common Stock, options or other equity incentive awards to employees, officers, directors or vendors of the
Company pursuant to any equity incentive plan duly adopted for such purpose, by the Company’s Board of Directors or a majority
of the members of a committee of the Board of Directors established for such purpose, (b) (1) any Shares issued to the Investor
pursuant to this Agreement, (2) any securities issued upon the exercise or exchange of or conversion of any shares of Common Stock
or Common Stock Equivalents held by the Investor at any time, or (3) any securities issued upon the exercise or exchange of or
conversion of any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities
referred to in this clause (3) have not been amended since the date of this Agreement to increase the number of such securities or
to decrease the exercise price, exchange price or conversion price of such securities, (c) securities issued pursuant to
acquisitions, divestitures, licenses, partnerships, collaborations or strategic transactions approved by the Company’s Board
of Directors or a majority of the members of a committee of directors established for such purpose, which acquisitions,
divestitures, licenses, partnerships, collaborations or strategic transactions can have a Variable Rate Transaction component,
provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its
subsidiaries, an operating company or an asset in a business synergistic with the business of the Company and shall provide to the
Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities,
(d) Common Stock issued by the Company to the Investor or an Affiliate of the Investor in connection with any “equity line of
credit” or other continuous offering or similar offering of Common Stock pursuant to a written agreement between the Company
and the Investor or an Affiliate of the Investor, whereby the Company may sell Common Stock to the Investor or an Affiliate of the
Investor at a future determined price or (e) Common Stock issued by the Company by any method deemed to be an “at the market
offering” as defined in Rule 415(a)(4) under the Securities Act, exclusively to or through Cantor Fitzgerald & Co., as the
Company’s sales agent, pursuant to one or more written agreements between the Company and Cantor Fitzgerald & Co.

 

“FINRA” means the Financial
Industry Regulatory Authority.

 

“Fundamental Transaction”
means that (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate or merge with or into (whether
or not the Company is the surviving corporation) another Person, with the result that the holders of the Company’s capital stock
immediately prior to such consolidation or merger together beneficially own less than 50% of the outstanding voting power of the surviving
or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of the
properties or assets of the Company to another Person, or (3) take action to facilitate a purchase, tender or exchange offer by another
Person that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (excluding any shares of Common Stock
held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender
or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person” or “group”
(as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by
issued and outstanding Common Stock.

 

     

     

    

 

 

“Governmental Authority”
means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory
or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or
arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision of any of the foregoing.

 

“Hazardous Material”
means any substance, material, or other matter regulated as toxic or hazardous, or as a contaminant or for which standards are imposed,
by any governmental authority because of its deleterious impact on the environment including but not limited to petroleum and petroleum
byproduct and distillates, asbestos and asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls, mold, radon gas,
radioactive substances, and poly- and perfluoroalkyl substances.

 

“Initial Registration Statement”
shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Investment Period” means
the period commencing on the Effective Date of the Initial Registration Statement and expiring on the date this Agreement is terminated
pursuant to Article VIII.

 

“Knowledge” means the
actual knowledge of the Company’s Chief Executive Officer, the Company’s President, and the Company’s Chief Financial
Officer, in each case after reasonable inquiry of all officers, directors and employees of the Company and its Subsidiaries who would
reasonably be expected to have knowledge or information with respect to the matter in question.

 

“Material Contracts”
means any other Contract that is expressly referred to in or filed or incorporated by reference as an exhibit to a Commission Document
or that, individually or in the aggregate, if terminated or subject to default by a party thereto, would have or would reasonably be expected
to have a Material Adverse Effect.

 

“New Registration Statement”
shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Post-Effective Amendment Period”
means the period commencing at 9:30 a.m., New York City time, on the fifth (5th) Trading Day immediately prior to the filing of any post-effective
amendment to the Initial Registration Statement or any New Registration Statement, and ending at 9:30 a.m., New York City time, on the
Trading Day immediately following, the Effective Date of such post-effective amendment.

 

“Person” means any person
or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated
organization, business association, firm, joint venture, governmental agency or authority.

 

“Personal
Information” means (a) information related to an identified or identifiable individual (e.g., name, address telephone
number, email address, financial account number, government-issued identifier), (b) any other data used or intended to be used or
which allows one to identify, contact, or precisely locate an individual, including any internet protocol address or other
persistent identifier, and (c) any other, similar information or data regulated by Privacy/Data Security Laws.

 

     

     

    

 

“Principal Market” means
the Nasdaq Capital Market; provided however, that in the event the Company’s Common Stock is ever listed or traded on the New York
Stock Exchange, the NYSE American, the Nasdaq Global Select Market, or the Nasdaq Global Market, then the “Principal Market”
shall mean such other market or exchange on which the Company’s Common Stock is then listed or traded.

 

“Privacy/Data Security Laws”
means all laws governing the receipt, collection, use, storage, processing, sharing, security, disclosure, or transfer of Personal Information
or the security of the Business Systems or Business Data.

 

“Prospectus” means the
prospectus in the form included in a Registration Statement, as supplemented from time to time by any Prospectus Supplement, including
the documents incorporated by reference therein.

 

“Prospectus Supplement”
means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under the Securities
Act, including the documents incorporated by reference therein.

 

“Registrable Securities”
shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Registration Statement”
shall have the meaning assigned to such term in the Registration Rights Agreement.

 

“Release” means disposing,
discharging, injecting, spilling, leaking, pumping, pouring, leaching, dumping, emitting, escaping or emptying into or upon, from, or
migrating through of Hazardous Materials, within or into, the air or any soil, sediment, subsurface strata, surface water or groundwater,
natural resources or structure.

 

“Remedial Action” means
any action required to investigate, clean up, remove or remediate, or conduct remedial, responsive, monitoring or corrective actions with
respect to, any presence or Release of Hazardous Materials.

 

“Rule 144” means Rule
144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same effect.

 

“Sale Price” means any
trade price for the shares of Common Stock on the Principal Market during normal trading hours, as reported by the Principal Market.

 

“Section 4(a)(2)” shall
have the meaning assigned to such term in the recitals of this Agreement.

 

“Securities Act” shall
mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.

 

     

     

    

 

“Shares” shall mean the
shares of Common Stock that are and/or may be purchased by the Investor under this Agreement pursuant to one or more VWAP Purchase Notices.

 

“Short Sales” shall mean
 “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act.

 

“Software” means all
computer software (in object code or source code format), data and databases, and related documentation and materials.

 

“Subsidiary” shall mean
any corporation or other entity, other than Support.com, Inc., of which at least a majority of the securities or other ownership interest
having ordinary voting power for the election of directors or other persons performing similar functions are at the time owned directly
or indirectly by the Company and/or any of its other Subsidiaries.

 

“Threshold Price” means
with respect to any particular VWAP Purchase Notice, the Sale Price on the VWAP Purchase Date equal to the greater of (i) 90% of the Closing
Sale Price on the Business Day immediately preceding the VWAP Purchase Date or (ii) such higher price as set forth by the Company in the
VWAP Purchase Notice.

 

“Total Commitment” shall
have the meaning assigned to such term in Section 2.1.

 

“Trading Day” shall mean
any day on which the Principal Market or, if the Common Stock is then listed on a Principal Market, such Principal Market is open for
trading (regular way), including any day on which the Principal Market (or such Principal Market, as applicable) is open for trading (regular
way) for a period of time less than the customary time.

 

“Transaction Documents”
means, collectively, this Agreement (as qualified by the Commission Documents) and the exhibits hereto, the Registration Rights Agreement
and the exhibits thereto, and each of the other agreements, documents, certificates and instruments entered into or furnished by the parties
hereto in connection with the transactions contemplated hereby and thereby.

 

“Variable
Rate Transaction” means a transaction in which the Company (i) issues or sells any equity or debt securities that are
convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock
Equivalents either at a conversion price, exercise price, exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for the Common Stock at any time after the initial issuance of such equity or debt securities, or
(ii) issues or sells any equity or debt securities, including without limitation, Common Stock or Common Stock Equivalents, either
(A) at a price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock (other than standard anti-dilution protection for any reorganization, recapitalization, non-cash dividend, stock split
or other similar transaction), or (B) that are subject to or contain any put, call, redemption, buy-back, price-reset or other
similar provision or mechanism (including, without limitation, a “Black-Scholes” put or call right, other than in
connection with a “fundamental transaction”) that provides for the issuance of additional equity securities of the
Company or the payment of cash by the Company, or (iii) enters into any agreement, including, but not limited to,
an “equity line of credit” or “at the market offering” or other continuous offering or similar
offering of Common Stock or Common Stock Equivalents, whereby the Company may sell Common Stock or Common Stock Equivalents at a
future determined price.

 

     

     

    

 

“VWAP” means, for the
Common Stock for a specified period, the dollar volume-weighted average price for the Common Stock on the Principal Market (or, if the
Common Stock is then listed on a Principal Market, on such Principal Market), for such period, as reported by Bloomberg through its “AQR”
function. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization
or other similar transaction during such period.

 

“VWAP Purchase Commencement Time”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, 9:30:01 a.m., New York City time, on the applicable VWAP Purchase
Date, or such later time on such VWAP Purchase Date publicly announced by the Principal Market (or, if the Common Stock is then listed
on an Principal Market, by such Principal Market) as the official open (or commencement) of trading (regular way) on the Principal Market
(or such Principal Market, as applicable) on such VWAP Purchase Date; provided, however, that if a VWAP Purchase Notice is delivered
after 9:00 a.m., New York City time, on a VWAP Purchase Date, then the VWAP Purchase Commencement Time shall start only upon receipt by
the Company of written confirmation (which may be by email) of acceptance by the Investor, and which confirmation shall specify the VWAP
Purchase Commencement Time.

 

“VWAP Purchase Date”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, the Trading Day on which the Investor receives, after 6:00 a.m.,
New York City time, but prior to 9:00 a.m., New York City time, on such Trading Day, a valid VWAP Purchase Notice for such VWAP Purchase
in accordance with this Agreement.

 

“VWAP Purchase Maximum Amount”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, a number of shares of Common Stock equal to the lesser of (i) a number
of shares of Common Stock which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor and its
affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial
ownership by the Investor of more than the Beneficial Ownership Limitation and (ii) a number of Shares equal to (A) the VWAP Purchase
Share Percentage multiplied by (B) the total number (or volume) of shares of Common Stock traded on the Principal Market (or, if the Common
Stock is then listed on an Principal Market, on such Principal Market) during the applicable VWAP Purchase Period on the applicable VWAP
Purchase Date for such VWAP Purchase and (iii) the VWAP Purchase Share Estimate.

 

“VWAP Purchase Notice”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, an irrevocable written notice delivered by the Company to the Investor
directing the Investor to purchase a VWAP Purchase Share Amount (such specified VWAP Purchase Share Amount subject to adjustment as set
forth in Section 3.1 as necessary to give effect to the VWAP Purchase Maximum Amount), at the applicable VWAP Purchase Price therefor
on the applicable VWAP Purchase Date for such VWAP Purchase in accordance with this Agreement.

 

     

     

    

 

“VWAP Purchase Period”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, the period on the applicable VWAP Purchase Date for such VWAP Purchase
beginning at the applicable VWAP Purchase Commencement Time and ending at the applicable VWAP Purchase Termination Time.

 

“VWAP Purchase Price”
means the purchase price per Share to be purchased by the Investor in such VWAP Purchase on such VWAP Purchase Date equal to ninety-six
and one-half percent (96.5%) of the VWAP over the applicable VWAP Purchase Period on such VWAP Purchase Date for such VWAP Purchase, to
be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar
transaction.

 

“VWAP Purchase Share Amount”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, the number of Shares to be purchased by the Investor in such VWAP
Purchase as specified by the Company in the applicable VWAP Purchase Notice, which number of Shares shall not exceed the applicable VWAP
Purchase Maximum Amount.

 

“VWAP Purchase Share Estimate”
means the number of shares of Common Stock constituting a good faith estimate by the Company
of the number of Shares that the Investor shall have the obligation to buy pursuant to the VWAP Purchase Notice.

 

“VWAP Purchase Share Percentage”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, twenty percent (20%).

 

“VWAP Purchase Termination Time”
means, with respect to a VWAP Purchase made pursuant to Section 3.1, 4:00 p.m., New York City time, on the applicable VWAP Purchase Date,
or such earlier time publicly announced by the Principal Market (or, if the Common Stock is then listed on a Principal Market, by such
Principal Market) as the official close of trading (regular way) on the Principal Market on such applicable VWAP Purchase Date.

 

     

     

    

 

EXHIBIT A

FORM OF REGISTRATION RIGHTS AGREEMENT

 

[TO BE FURNISHED SEPARATELY]

 

     

     

    

 

EXHIBIT B

CLOSING CERTIFICATE 

 

[•], 202[•]

 

The undersigned, the [•] of Wejo Group Limited, an exempted company
limited by shares incorporated under the laws of Bermuda (the “Company”), delivers this certificate in connection
with the Common Stock Purchase Agreement, dated as of [•] (the “Agreement”), by and between the Company
and CF Principal Investments LLC, a Delaware limited liability company (the “Investor”), and hereby certifies
on the date hereof that (capitalized terms used herein without definition have the meanings assigned to them in the Agreement):

 

1. Attached hereto as Exhibit A is a true, complete and correct
copy of the Amended and Restated Certificate of Incorporation of the Company, as amended through the date hereof, as filed with the Registrar
of Companies of Bermuda (the “Certificate of Incorporation”). The Certificate of Incorporation of the Company
has not been further amended or restated, and no document with respect to any amendment to the Certificate of Incorporation of the Company
has been filed in the office of the Registrar of Companies of Bermuda since the date shown on the face of the state certification relating
to the Certificate of Incorporation, which is in full force and effect on the date hereof, and no action has been taken by the Company
in contemplation of any such amendment or the dissolution, merger or consolidation of the Company.

 

2. Attached hereto as Exhibit B is a true and complete copy
of the Amended and Restated Bylaws of the Company, as amended and restated through, and as in full force and effect on, the date hereof
(the “Bye-laws”), and no proposal for any amendment, repeal or other modification to the Bylaws of the Company
has been taken or is currently pending before the Board of Directors or stockholders of the Company.

 

3. The Board of Directors of the Company has approved the transactions
contemplated by the Transaction Documents; said approval has not been amended, rescinded or modified and remains in full force and effect
as of the date hereof. Attached hereto as Exhibit C are true, correct and complete copies of the resolutions approving the Agreement
duly adopted by the Board of Directors of the Company on [•], 202[•].

 

4. Each person who, as an officer of the Company, or as attorney-in-fact
of an officer of the Company, signed the Transaction Documents to which the Company is a party, was duly elected, qualified and acting
as such officer or duly appointed and acting as such attorney-in-fact, and the signature of each such person appearing on any such document
is his genuine signature.

 

IN WITNESS WHEREOF, I have signed my name as of the date first
above written.

 

	 	 
	 	Name:
	 	Title:

 

     

     

    

 

EXHIBIT C

 

COMPLIANCE CERTIFICATE 

 

The undersigned, the [•] of Wejo Group Limited, an exempted company
limited by shares incorporated under the laws of Bermuda (the “Company”), delivers this certificate in connection
with the Common Stock Purchase Agreement, dated as of [•] (the “Agreement”), by and between the Company
and CF Principal Investments LLC, a Delaware limited liability company (the “Investor”), and hereby certifies
on the date hereof that, to the best of his or her knowledge after reasonable investigation, on behalf of the Company (capitalized terms
used herein without definition have the meanings assigned to them in the Agreement):

 

1. The undersigned is the duly appointed [•] of the Company.

 

2. Except as set forth in the Commission Documents, the representations
and warranties of the Company set forth in Article V of the Agreement (i) that are not qualified by “materiality” or “Material
Adverse Effect” are true and correct in all material respects as of [the Commencement Date] [the date hereof] with the same force
and effect as if made on [the Commencement Date] [the date hereof], except to the extent such representations and warranties are as of
another date, in which case, such representations and warranties are true and correct in all material respects as of such other date and
(ii) that are qualified by “materiality” or “Material Adverse Effect” are true and correct as of [the Commencement
Date] [the date hereof] with the same force and effect as if made on [the Commencement Date] [the date hereof], except to the extent such
representations and warranties are as of another date, in which case, such representations and warranties are true and correct as of such
other date.

 

3. The Company has performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by the Agreement and the Registration Rights Agreement to be performed,
satisfied or complied with by the Company [at or prior to Commencement] [on or prior to the date hereof].

 

4. The Shares issuable in respect of each VWAP Purchase Notice effected
pursuant to the Agreement shall be delivered to the Investor electronically as DWAC Shares, and shall be freely tradable and transferable
and without restriction on resale and without any stop transfer instructions maintained against such Shares.

 

5. As of [the Commencement Date] [the date hereof], the Company does
not possess any material non-public information.

 

6. As of [the Commencement Date] [the date hereof], the Company has
reserved out of its authorized and unissued Common Stock [•] shares of Common Stock solely for the purpose of effecting VWAP Purchases
under the Agreement.

 

7. No stop order suspending the effectiveness of the Registration Statement
or the use of the Prospectus under the Securities Act has been issued and no proceedings for such purpose or pursuant to Section 8A of
the Securities Act are pending before or, to the knowledge of the Company, threatened by the Commission.

 

     

     

    

 

The undersigned has executed this Certificate this [•] day of
[•], 202[•].

 

	 	By:	 

	 	Name:	 

	 	Title:	 

 

     

     

    

 

EXHIBIT D

 

FORM OF VWAP PURCHASE NOTICE

 

 

 

		From:	[Company Name]

		To:	CF Principal Investments LLC

		Attention:	Chief Operating Officer

		Copy to:	CFControlledEquityOffering@cantor.com

 

		Subject:	VWAP Purchase Notice

 

		Date:	[•], 202[•]

		Time:	[•]

 

Ladies and Gentlemen:

 

Pursuant to the terms and subject to the conditions contained in the
Common Stock Purchase Agreement (the “Agreement”) between Wejo Group Limited, an exempted company limited by
shares incorporated under the laws of Bermuda (the “Company”), and CF Principal Investments LLC (the “Investor”),
dated [•], 2022, the Company hereby directs the Investor to purchase a VWAP Purchase Share Estimate equal to [•] shares of the
Company’s common stock, par value $0.001 per share, which the Company represents is no greater than the VWAP Purchase Maximum Amount
(as defined in the Agreement), at the relevant VWAP Purchase Price (as defined in the Agreement). The Company represents that all conditions
set forth in Section 7.3 of the Agreement have been satisfied.

 

	 	Wejo Group Limited

 

	 	By:	                   
	 	Name:
	 	Title:
	 	 	 
	 	 	 
	 	CF Principal Investments LLC

 

	 	By:	                   
	 	Name:
	 	Title:Exhibit 10.2

 

REGISTRATION RIGHTS AGREEMENT 

 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”),
dated as of February 14, 2022, is by and between CF Principal Investments LLC, a Delaware limited liability company (the “Investor”),
and Wejo Group Limited, an exempted company limited by shares incorporated under the laws of Bermuda (the “Company”).

RECITALS 

 

The Company and the Investor have entered into
that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant
to which the Company may issue, from time to time, to the Investor up to the lesser of (i) $100,000,000 in aggregate gross purchase price
of newly issued shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and
(ii) the Exchange Cap (to the extent applicable under Section 3.3 of the Purchase Agreement), as provided for therein.

 

Pursuant to the terms of, and in consideration
for the Investor entering into, the Purchase Agreement, the Company shall cause to be issued to the Investor the Commitment Shares in
accordance with the terms of the Purchase Agreement.

 

Pursuant to the terms of, and in consideration
for the Investor entering into, the Purchase Agreement, and to induce the Investor to execute and deliver the Purchase Agreement, the
Company has agreed to provide the Investor with certain registration rights with respect to the Registrable Securities (as defined herein)
as set forth herein.

AGREEMENT 

 

NOW,
THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein and in the Purchase
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, intending to be
legally bound hereby, the Company and the Investor hereby agree as follows:

ARTICLE I

DEFINITIONS

 

1.      Definitions. Capitalized terms used herein and not otherwise
defined herein shall have the respective meanings set forth in the Purchase Agreement. As used in this Agreement, the following terms
shall have the following meanings:

 

“Business Day” means
any day other than Saturday, Sunday or any other day on which commercial banks in New York, New York are authorized or required by law
to remain closed.

 

“Closing Date” shall
mean the date of this Agreement.

 

     

     

    

 

“Commission” means the
U.S. Securities and Exchange Commission or any successor entity.

 

“Effective Date” means
the date that the applicable Registration Statement has been declared effective by the Commission.

 

“Effectiveness Deadline”
means (i) with respect to the Initial Registration Statement required to be filed to pursuant to Section 2(a), the
earlier of (A) the 90th calendar day after the Filing Deadline, if such Registration Statement is subject to review by the
Commission, and (B) the 60th calendar day after the Filing Deadline, if the Company is notified (orally or in writing, whichever
is earlier) by the Commission that such Registration Statement will not be reviewed and (ii) with respect to any New Registration Statements
that may be required to be filed by the Company pursuant to this Agreement, the earlier of (A) the 90th calendar day following
the date on which the Company was required to file such additional Registration Statement, if such Registration Statement is subject
to review by the Commission, and (B) the 45th calendar day following the date on which the Company was required to file such
New Registration Statement, if the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration
Statement will not be reviewed.

 

“Eligible
Market” means The New York Stock Exchange, Inc., NYSE AMEX Equities, the NASDAQ Global Select Market, The NASDAQ
Global Market or the NASDAQ Capital Market.

 

“Filing Deadline” means
(i) with respect to the Initial Registration Statement required to be filed to pursuant to Section 2(a), the 10th
Business Day after the due date in accordance with the Exchange Act (without reference to any extensions pursuant to Rule 12b-25)
of the Company’s Annual Report on Form 10-K with respect to the year ended December 31, 2021 and (ii) with respect to any New Registration
Statements that may be required to be filed by the Company pursuant to this Agreement, the 10th Business Day following the
sale of substantially all of the Registrable Securities included in the Initial Registration Statement or the most recent prior New Registration
Statement, as applicable, or such other date as permitted by the Commission.

 

“Person” means any person
or entity, whether a natural person, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated
organization, business association, firm, joint venture, governmental agency or authority.

 

“Prospectus” means the
prospectus in the form included in the Registration Statement at the applicable Effective Date of the Registration Statement, as supplemented
from time to time by any Prospectus Supplement, including the documents incorporated by reference therein.

 

“Prospectus Supplement”
means any prospectus supplement to the Prospectus filed with the Commission from time to time pursuant to Rule 424(b) under the Securities
Act, including the documents incorporated by reference therein.

 

“register,” “registered,”
and “registration” refer to a registration effected by preparing and filing one or more Registration Statements
in compliance with the Securities Act and pursuant to Rule 415 and the declaration of effectiveness of such Registration Statement(s)
by the Commission.

 

    2

     

    

 

“Registrable Securities”
means all of (i) the Shares and the Commitment Shares and (ii) any capital stock of the Company issued or issuable with respect to such
Shares or Commitment Shares, including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange
or similar event or otherwise and (2) shares of capital stock of the Company into which the shares of Common Stock are converted or exchanged
and shares of capital stock of a successor entity into which the shares of Common Stock are converted or exchanged, in each case until
such time as such securities cease to be Registrable Securities pursuant to Section 2(f).

 

“Registration Statement”
means a registration statement or registration statements of the Company filed under the Securities Act covering the resale by the Investor
of Registrable Securities, as such registration statement or registration statements may be amended and supplemented from time to time,
including all documents filed as part thereof or incorporated by reference therein.

 

“Rule 144” means Rule
144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar or successor
rule or regulation of the Commission that may at any time permit the Investor to sell securities of the Company to the public without
registration.

 

“Rule 415” means Rule
415 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar or successor
rule or regulation of the Commission providing for offering securities on a delayed or continuous basis.

 

“Trading
Market” means NASDAQ Global Market.

 

ARTICLE II

REGISTRATIONS

2. Registration.

 

(a) Mandatory Registration. The Company
shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the Commission the Initial Registration
Statement on Form S-1 (or any successor form) covering the resale by the Investor of (i) all of the Commitment Shares and (ii) the maximum
number of additional Registrable Securities as shall be permitted to be included thereon in accordance with applicable Commission rules,
regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor under Rule 415 under
the Securities Act at then prevailing market prices (and not fixed prices) (the “Initial Registration Statement”).
The Initial Registration Statement shall contain the “Selling Stockholder” and “Plan of Distribution” sections
in substantially the form attached hereto as Exhibit B. The Company shall use its commercially reasonable efforts to have
the Initial Registration Statement declared effective by the Commission as soon as reasonably practicable, but in no event later than
the applicable Effectiveness Deadline following the filing thereof with the Commission.

 

    3

     

    

 

(b) Legal Counsel. Subject to Section 5
hereof, the Investor shall have the right to select one legal counsel to review and oversee, solely on its behalf, any registration pursuant
to this Section 2 (“Legal Counsel”), which shall be King & Spalding LLP, or such other counsel as thereafter
designated by the Investor. Except as provided under Section 10.1(i) of the Purchase Agreement, the Company shall have no obligation to
reimburse the Investor for any and all legal fees and expenses of the Legal Counsel incurred in connection with the transactions contemplated
hereby.

 

(c) Sufficient Number of Shares Registered.
If at any time all Registrable Securities are not covered by the Initial Registration Statement filed pursuant to Section 2(a) as a result
of Section 2(e) or otherwise, the Company shall use its commercially reasonable efforts to file with the Commission one or more additional
Registration Statements so as to cover all of the Registrable Securities not covered by such initial Registration Statement, in each case,
as soon as practicable (taking into account any position of the staff of the Commission (“Staff”) with respect
to the date on which the Staff will permit such additional Registration Statement(s) to be filed with the Commission and the rules and
regulations of the Commission) (each such additional Registration Statement, a “New Registration Statement”)
but in no event later than the applicable Filing Deadline for such New Registration Statement. The Company shall use its commercially
reasonable efforts to cause each such New Registration Statement to become effective as soon as reasonably practicable following the filing
thereof with the Commission, but in no event later than the applicable Effectiveness Deadline for such New Registration Statement.

 

(d) No Inclusion of Other Securities. In
no event shall the Company include any securities other than Registrable Securities on any Registration Statement pursuant to Section
2(a) or Section 2(c) without consulting the Investor and Legal Counsel prior to filing such Registration Statement with the Commission.

 

(e) Offering. If the Staff or the Commission
seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of
securities that does not permit such Registration Statement to become effective and be used for resales by the Investor on a delayed or
continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices), or if after the filing of any Registration Statement
pursuant to Section 2(a) or Section 2(c), the Company is otherwise required by the Staff or the Commission to reduce the number of Registrable
Securities included in such Registration Statement, then the Company shall reduce the number of Registrable Securities to be included
in such Registration Statement (after consultation with the Investor and Legal Counsel as to the specific Registrable Securities to be
removed therefrom) until such time as the Staff and the Commission shall so permit such Registration Statement to become effective and
be used as aforesaid. Notwithstanding anything in this Agreement to the contrary, if after giving effect to the actions referred to in
the immediately preceding sentence, the Staff or the Commission does not permit such Registration Statement to become effective and be
used for resales by the Investor on a delayed or continuous basis under Rule 415 at then-prevailing market prices (and not fixed prices),
the Company shall not request acceleration of the Effective Date of such Registration Statement, the Company shall promptly (but in no
event later than 48 hours) request the withdrawal of such Registration Statement pursuant to Rule 477 under the Securities Act, and the
Effectiveness Deadline shall automatically be deemed to have elapsed with respect to such Registration Statement at such time as the Staff
or the Commission has made a final and non-appealable determination that the Commission will not permit such Registration Statement to
be so utilized (unless prior to such time the Company has received assurances from the Staff or the Commission that a New Registration
Statement filed by the Company with the Commission promptly thereafter may be so utilized). In the event of any reduction in Registrable
Securities pursuant to this paragraph, the Company shall use its commercially reasonable efforts to file one or more New Registration
Statements with the Commission in accordance with Section 2(c) until such time as all Registrable Securities have been included in Registration
Statements that have been declared effective and the Prospectuses contained therein are available for use by the Investor.

 

    4

     

    

 

(f) Any Registrable Security shall cease to be
a “Registrable Security” at the earliest of the following: (i) when a Registration Statement covering such Registrable Security
becomes or has been declared effective by the Commission and such Registrable Security has been sold or disposed of pursuant to such effective
Registration Statement; (ii) when such Registrable Security is held by the Company or one of its Subsidiaries; and (iii) the date that
is the first (1st) anniversary of the date of termination of the Purchase Agreement in accordance with Article VIII of the Purchase Agreement.

 

ARTICLE III

RELATED OBLIGATIONS

 

3. Related Obligations. The Company shall use its commercially
reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof,
and, pursuant thereto, during the term of this Agreement, the Company shall have the following obligations:

 

(a) The Company shall promptly prepare and file
with the Commission the Initial Registration Statement pursuant to Section 2(a) hereof and one or more New Registration Statements pursuant
to Section 2(c) hereof with respect to the Registrable Securities, but in no event later than the applicable Filing Deadline therefor,
and the Company shall use its commercially reasonable efforts to cause each such Registration Statement to become effective as soon as
practicable after such filing, but in no event later than the applicable Effectiveness Deadline therefor. Subject to Allowable Grace Periods,
the Company shall keep each Registration Statement effective (and the Prospectus contained therein available for use) pursuant to Rule
415 for resales by the Investor on a continuous basis at then-prevailing market prices (and not fixed prices) at all times until the earlier
of (i) the date on which the Investor shall have sold all of the Registrable Securities covered by such Registration Statement and (ii)
the date of termination of the Purchase Agreement if as of such termination date the Investor holds no Registrable Securities (or, if
applicable, the date on which such securities cease to be Registrable Securities after the date of termination of the Purchase Agreement)
(the “Registration Period”). Notwithstanding anything to the contrary contained in this Agreement (but subject
to the provisions of Section 3(p) hereof), the Company shall ensure that, when filed and at all times while effective, each Registration
Statement (including, without limitation, all amendments and supplements thereto) and the Prospectus (including, without limitation, all
amendments and supplements thereto) used in connection with such Registration Statement shall not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of Prospectuses,
in the light of the circumstances in which they were made) not misleading. The Company shall submit to the Commission, as soon as reasonably
practicable after the date that the Company learns that no review of a particular Registration Statement will be made by the Staff or
that the Staff has no further comments on a particular Registration Statement (as the case may be), a request for acceleration of effectiveness
of such Registration Statement to a time and date as soon as reasonably practicable in accordance with Rule 461 under the Securities Act.

 

    5

     

    

 

(b) Subject to Section 3(p) of this Agreement,
the Company shall use its commercially reasonable efforts to prepare and file with the Commission such amendments (including, without
limitation, post-effective amendments) and supplements to each Registration Statement and the Prospectus used in connection with each
such Registration Statement, which Prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary
to keep each such Registration Statement effective (and the Prospectus contained therein current and available for use) at all times during
the Registration Period for such Registration Statement, and, during such period, comply with the provisions of the Securities Act with
respect to the disposition of all Registrable Securities of the Company required to be covered by such Registration Statement until such
time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition by the Investor.
Without limiting the generality of the foregoing, the Company covenants and agrees that (i) at or before 8:30 a.m. (New York City time)
on the second (2nd) Trading Day immediately following the Effective Date of the Initial Registration Statement and any New Registration
Statement (or any post-effective amendment thereto), the Company shall file with the Commission in accordance with Rule 424(b) under the
Securities Act the final Prospectus to be used in connection with sales pursuant to such Registration Statement (or post-effective amendment
thereto), and (ii) if the transactions contemplated by any VWAP Purchase are material to the Company (individually or collectively with
all other prior VWAP Purchases, the consummation of which have not previously been reported in any Prospectus Supplement filed with the
Commission under Rule 424(b) under the Securities Act or in any report, statement or other document filed by the Company with the Commission
under the Exchange Act), or if otherwise required under the Securities Act (or the interpretations of the Commission thereof), in each
case as reasonably determined by the Company and the Investor, then, at or before 8:30 a.m., New York City time, on the first (1st) Trading
Day immediately following the VWAP Purchase Date, if a VWAP Purchase Notice was properly delivered to the Investor hereunder in connection
with such VWAP Purchase, the Company shall file with the Commission a Prospectus Supplement pursuant to Rule 424(b) under the Securities
Act with respect to the VWAP Purchase(s), the total VWAP Purchase Price for the Shares subject to such VWAP Purchase(s) (as applicable),
the applicable VWAP Purchase Price(s) for such Shares and the net proceeds that are to be (and, if applicable, have been) received by
the Company from the sale of such Shares. To the extent not previously disclosed in the Prospectus or a Prospectus Supplement, the Company
shall disclose in its Quarterly Reports on Form 10-Q and in its Annual Reports on Form 10-K the information described in the immediately
preceding sentence relating to all VWAP Purchase(s) consummated during the relevant fiscal quarter and shall file such Quarterly Reports
and Annual Reports with the Commission within the applicable time period prescribed for such report under the Exchange Act. In the case
of amendments and supplements to any Registration Statement on Form S-1 or Prospectus related thereto which are required to be filed pursuant
to this Agreement (including, without limitation, pursuant to this Section 3(b)) by reason of the Company filing a report on Form 8-K,
Form 10-Q or Form 10-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into
such Registration Statement and Prospectus, if applicable, or shall file such amendments or supplements to the Registration Statement
or Prospectus with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company
to amend or supplement such Registration Statement or Prospectus, for the purpose of including or incorporating such report into such
Registration Statement and Prospectus. The Company consents to the use of the Prospectus (including, without limitation, any supplement
thereto) included in each Registration Statement in accordance with the provisions of the Securities Act and with the securities or “Blue
Sky” laws of the jurisdictions in which the Registrable Securities may be sold by the Investor, in connection with the resale of
the Registrable Securities and for such period of time thereafter as such Prospectus (including, without limitation, any supplement thereto)
(or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be delivered
in connection with resales of Registrable Securities.

 

    6

     

    

 

(c) The Company shall (A) permit Legal Counsel
an opportunity to review and comment upon (i) each Registration Statement at least five (5) Business Days prior to its filing with the
Commission and (ii) all amendments and supplements to each Registration Statement (including, without limitation, the Prospectus contained
therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor
reports or Prospectus Supplements the contents of which is limited to that set forth in such reports) within a reasonable number of days
prior to their filing with the Commission, and (B) shall reasonably consider any comments of the Investor and Legal Counsel on any such
Registration Statement or amendment or supplement thereto or to any Prospectus contained therein. The Company shall promptly furnish to
Legal Counsel, without charge, (i) electronic copies of any correspondence from the Commission or the Staff to the Company or its representatives
relating to each Registration Statement (which correspondence shall be redacted to exclude any material, non-public information regarding
the Company or any of its Subsidiaries), (ii) after the same is prepared and filed with the Commission, one (1) electronic copy of each
Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules,
all documents incorporated therein by reference, if requested by the Investor, and all exhibits and (iii) upon the effectiveness of each
Registration Statement, one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and supplements
thereto; provided, however, the Company shall not be required to furnish any document (other than the Prospectus, which may be provided
in .PDF format) to Legal Counsel to the extent such document is available on EDGAR at the time of Legal Counsel’s request).

 

(d) Without limiting any obligation of the Company
under the Purchase Agreement, the Company shall promptly furnish to the Investor, without charge, (i) after the same is prepared and filed
with the Commission, at least one (1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including,
without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by the Investor,
all exhibits thereto, (ii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included in
such Registration Statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably
request from time to time) and (iii) such other documents, including, without limitation, copies of any final Prospectus and any Prospectus
Supplement thereto, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable
Securities owned by the Investor; provided, however, the Company shall not be required to furnish any document (other than the Prospectus,
which may be provided in .PDF format) to the Investor to the extent such document is available on EDGAR).

 

    7

     

    

 

(e) The Company shall take such action as is reasonably
necessary to (i) register and qualify, unless an exemption from registration and qualification applies, the resale by the Investor of
the Registrable Securities covered by a Registration Statement under such other securities or “Blue Sky” laws of all applicable
jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments (including, without limitation, post-effective
amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during
the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications
in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the
Registrable Securities for sale in such jurisdictions; provided, however, the Company shall not be required in connection
therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify
but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of
process in any such jurisdiction. The Company shall promptly notify Legal Counsel and the Investor of the receipt by the Company of any
notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the
securities or “Blue Sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or
threatening of any proceeding for such purpose.

 

(f) The Company shall notify Legal Counsel and
the Investor in writing of the happening of any event, as promptly as reasonably practicable after becoming aware of such event, as a
result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact
or omits to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading (provided that in no event shall such notice contain any material, non-public information regarding
the Company or any of its Subsidiaries), and, subject to Section 3(p), promptly prepare a supplement or amendment to such Registration
Statement and such Prospectus contained therein to correct such untrue statement or omission and deliver one (1) electronic copy of such
supplement or amendment to Legal Counsel and the Investor (or such other number of copies as Legal Counsel or the Investor may reasonably
request). The Company shall also promptly notify Legal Counsel and the Investor in writing (i) when a Prospectus or any Prospectus Supplement
or post-effective amendment has been filed, when a Registration Statement or any post-effective amendment has become effective (notification
of such effectiveness shall be delivered to Legal Counsel and the Investor by facsimile or e-mail on the same day of such effectiveness),
and when the Company receives written notice from the Commission that a Registration Statement or any post-effective amendment will be
reviewed by the Commission, (ii) of any request by the Commission for amendments or supplements to a Registration Statement or related
Prospectus or related information, (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration
Statement would be appropriate and (iv) of the receipt of any request by the Commission or any other federal or state governmental authority
for any additional information relating to the Registration Statement or any amendment or supplement thereto or any related Prospectus.
The Company shall respond as promptly as reasonably practicable to any comments received from the Commission with respect to a Registration
Statement or any amendment thereto. Nothing in this Section 3(f) shall limit any obligation of the Company under the Purchase Agreement.

 

    8

     

    

 

(g) The Company shall (i) use its commercially
reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement or the use
of any Prospectus contained therein, or the suspension of the qualification, or the loss of an exemption from qualification, of any of
the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such
order or suspension at the earliest possible time and (ii) notify Legal Counsel and the Investor of the issuance of such order and the
resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding.

 

(h) The Company shall hold in confidence and not
make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure of such information is necessary
to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement
or omission in any Registration Statement or is otherwise required to be disclosed in such Registration Statement pursuant to the Securities
Act, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental
body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation
of this Agreement or any other Transaction Document. The Company agrees that it shall, upon learning that disclosure of such information
concerning the Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt
written notice to the Investor and allow the Investor, at the Investor’s expense, to undertake appropriate action to prevent disclosure
of, or to obtain a protective order for, such information.

 

(i) Without limiting any obligation of the Company
under the Purchase Agreement, the Company shall use its commercially reasonable efforts either to (i) cause all of the Registrable Securities
covered by each Registration Statement to be listed on the Trading Market, or (ii) secure designation and quotation of all of the Registrable
Securities covered by each Registration Statement on another Eligible Market. The Company shall pay all fees and expenses in connection
with satisfying its obligation under this Section 3(i).

 

(j) The Company shall cooperate with the Investor
and, to the extent applicable, facilitate the timely preparation and delivery of Registrable Securities, as DWAC Shares, to be offered
pursuant to a Registration Statement and enable such DWAC Shares to be in such denominations or amounts (as the case may be) as the Investor
may reasonably request from time to time. Investor hereby agrees that it shall cooperate with the Company, its counsel and Transfer Agent
in connection with any issuances of DWAC Shares, and hereby represents, warrants and covenants to the Company that that it will resell
such DWAC Shares only pursuant to the Registration Statement in which such DWAC Shares are included, in a manner described under the caption
 “Plan of Distribution” in such Registration Statement, and in a manner in compliance with all applicable U.S. federal and
state securities laws, rules and regulations, including, without limitation, any applicable prospectus delivery requirements of the Securities
Act. At the time such DWAC shares sold pursuant to the Registration Statement, such DWAC Shares shall be free from all restrictive legends
may be transmitted by the Transfer Agent to the Investor by crediting an account at DTC as directed in writing by the Investor.

 

    9

     

    

 

(k) Upon the written request of the Investor, the
Company shall as soon as reasonably practicable after receipt of notice from the Investor and subject to Section 3(p) hereof, (i) incorporate
in a Prospectus Supplement or post-effective amendment such information as the Investor reasonably requests to be included therein relating
to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable
Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable Securities
to be sold in such offering; (ii) make all required filings of such Prospectus Supplement or post-effective amendment after being notified
of the matters to be incorporated in such Prospectus Supplement or post-effective amendment; and (iii) supplement or make amendments to
any Registration Statement or Prospectus contained therein if reasonably requested by the Investor.

 

(l) The Company shall use its commercially reasonable
efforts to cause the Registrable Securities covered by a Registration Statement to be registered with or approved by such other governmental
agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities.

 

(m) The Company shall make generally available
to its security holders (which may be satisfied by making such information available on EDGAR) as soon as practical, but not later than
ninety (90) days after the close of the period covered thereby, an earnings statement (in form complying with, and in the manner provided
by, the provisions of Rule 158 under the Securities Act) covering a twelve-month period beginning not later than the first day of the
Company’s fiscal quarter next following the applicable Effective Date of each Registration Statement.

 

(n) The Company shall otherwise use its commercially
reasonable efforts to comply with all applicable rules and regulations of the Commission in connection with any registration hereunder.

 

(o) Within one (1) Business Day after each Registration
Statement which covers Registrable Securities is declared effective by the Commission, the Company shall deliver, and shall cause legal
counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to the Investor) confirmation that
such Registration Statement has been declared effective by the Commission in the form attached hereto as Exhibit A.

 

    10

     

    

 

(p) Notwithstanding anything to the contrary contained
herein (but subject to the last sentence of this Section 3(p)), at any time after the Effective Date of a particular Registration Statement,
the Company may, upon written notice to Investor, suspend Investor’s use of any prospectus that is a part of any Registration Statement
(in which event the Investor shall discontinue sales of the Registrable Securities pursuant to such Registration Statement contemplated
by this Agreement, but shall settle any previously made sales of Registrable Securities) if the Company (x) is pursuing an acquisition,
merger, tender offer, reorganization, disposition or other similar transaction and the Company determines in good faith that (A) the Company’s
ability to pursue or consummate such a transaction would be materially adversely affected by any required disclosure of such transaction
in such Registration Statement or other registration statement or (B) such transaction renders the Company unable to comply with Commission
requirements, in each case under circumstances that would make it impractical or inadvisable to cause any Registration Statement (or such
filings) to be used by Investor or to promptly amend or supplement any Registration Statement contemplated by this Agreement on a post
effective basis, as applicable, or (y) has experienced some other material non-public event the disclosure of which at such time, in the
good faith judgment of the Company, would materially adversely affect the Company (each, an “Allowable Grace Period”);
provided, however, that in no event shall the Investor be suspended from selling Registrable Securities pursuant to any Registration
Statement for a period that exceeds twenty (20) consecutive Trading Days or an aggregate of sixty (60) days in any three hundred and sixty-five
(365)-day period; and provided, further, the Company shall not effect any such suspension during (A) the first 10 consecutive Trading
Days after the Effective Date of the particular Registration Statement or (B) the three-Trading Day period following the VWAP Purchase
Share Delivery Date for each VWAP Purchase. Upon disclosure of such information or the termination of the condition described above, the
Company shall provide prompt notice, but in any event within one Business Day of such disclosure or termination, to the Investor and shall
promptly terminate any suspension of sales it has put into effect and shall take such other reasonable actions to permit registered sales
of Registrable Securities as contemplated in this Agreement (including as set forth in the first sentence of Section 3(f) with respect
to the information giving rise thereto unless such material, non-public information is no longer applicable). Notwithstanding anything
to the contrary contained in this Section 3(p), the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the
Investor in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to
which (i) the Company has made a sale to Investor and (ii) the Investor has entered into a contract for sale, and delivered a copy of
the Prospectus included as part of the particular Registration Statement to the extent applicable, in each case prior to the Investor’s
receipt of the notice of an Allowable Grace Period and for which the Investor has not yet settled.

 

ARTICLE IV

OBLIGATIONS OF THE INVESTOR

4.       Obligations
of the Investor.

 

(a) At least five (5) Business Days prior to the
first anticipated filing date of each Registration Statement (or such shorter period to which the parties agree), the Company shall notify
the Investor in writing of the information the Company requires from the Investor with respect to such Registration Statement. It shall
be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the
Registrable Securities of the Investor that the Investor shall furnish to the Company such information regarding itself, the Registrable
Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required
to effect and maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents in connection
with such registration as the Company may reasonably request.

 

    11

     

    

 

(b) The Investor, by its acceptance of the Registrable
Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of each Registration Statement hereunder, unless the Investor has notified the Company in writing of the Investor’s election to
exclude all of the Investor’s Registrable Securities from such Registration Statement.

 

(c) The Investor agrees that, upon receipt of any
notice from the Company of the happening of any event of the kind described in Section 3(p) or the first sentence of 3(f), the Investor
shall as soon as is reasonably practicable discontinue disposition of Registrable Securities pursuant to any Registration Statement(s)
covering such Registrable Securities until the Investor’s receipt of the copies of the supplemented or amended Prospectus contemplated
by Section 3(p) or the first sentence of Section 3(f) or receipt of notice that no supplement or amendment is required. Notwithstanding
anything to the contrary in this Section 4(c), the Company shall cause its transfer agent to deliver DWAC Shares to a transferee of the
Investor in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to
which the Investor has entered into a contract for sale prior to the Investor’s receipt of a notice from the Company of the happening
of any event of the kind described in Section 3(p) or the first sentence of Section 3(f) and for which the Investor has not yet settled.

 

(d) The Investor covenants and agrees that it shall
comply with the prospectus delivery and other requirements of the Securities Act as applicable to it in connection with sales of Registrable
Securities pursuant to a Registration Statement.

 

ARTICLE V

EXPENSES OF REGISTRATION

 

5.       Expenses of
Registration.

 

All reasonable expenses of the Company, other than
sales or brokerage commissions and fees and disbursements of counsel for, and other expenses of, the Investor, incurred in connection
with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and
qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.

 

    12

     

    

 

ARTICLE VI

INDEMNIFICATION

 

6.       Indemnification.

 

(a) In the event any Registrable Securities are
included in any Registration Statement under this Agreement, to the fullest extent permitted by law, the Company will, and hereby does,
indemnify, hold harmless and defend the Investor, each of its directors, officers, shareholders, members, partners, employees, agents,
representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of
such title or any other title) and each Person, if any, who controls the Investor within the meaning of the Securities Act or the Exchange
Act and each of the directors, officers, shareholders, members, partners, employees, agents, representatives (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling
Persons (each, an “Investor Party” and collectively, the “Investor Parties”), against
any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without
limitation, court costs, reasonable attorneys’ fees, costs of defense and investigation), amounts paid in settlement or expenses,
joint or several, (collectively, “Claims”) reasonably incurred in investigating, preparing or defending any
action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the Commission, whether pending or threatened, whether or not an Investor Party is or may be a party
thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions
or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged
untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection
with the qualification of the offering under the securities or other “Blue Sky” laws of any jurisdiction in which Registrable
Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required
to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement
of a material fact contained in any Prospectus (as amended or supplemented) or in any Prospectus Supplement or the omission or alleged
omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the
statements therein were made, not misleading (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”).
Subject to Section 6(c), the Company shall reimburse the Investor Parties, promptly as such expenses are incurred and are due and payable,
for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim.
Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not
apply to a Claim by an Investor Party arising out of or based upon a Violation which occurs in reliance upon and in conformity with information
furnished in writing to the Company by such Investor Party for such Investor Party expressly for use in connection with the preparation
of such Registration Statement, Prospectus or Prospectus Supplement or any such amendment thereof or supplement thereto (it being hereby
acknowledged and agreed that the written information set forth on Exhibit C attached hereto is the only written information furnished
to the Company by or on behalf of the Investor expressly for use in any Registration Statement, Prospectus or Prospectus Supplement);
(ii) shall not be available to the Investor to the extent such Claim is based on a failure of the Investor to deliver or to cause to be
delivered the Prospectus (as amended or supplemented) made available by the Company (to the extent applicable), including, without limitation,
a corrected Prospectus, if such Prospectus (as amended or supplemented) or corrected Prospectus was timely made available by the Company
pursuant to Section 3(d) and then only if, and to the extent that, following the receipt of the corrected Prospectus no grounds for such
Claim would have existed; and (iii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without
the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in
full force and effect regardless of any investigation made by or on behalf of the Investor Party.

 

    13

     

    

 

(b) In connection with any Registration Statement
in which the Investor is participating, the Investor agrees to severally and not jointly indemnify, hold harmless and defend, to the same
extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers who signs the
Registration Statement and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act
(each, an “Company Party”), against any Claim or Indemnified Damages to which any of them may become subject,
under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any
Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with written
information relating to the Investor furnished to the Company by the Investor expressly for use in connection with such Registration Statement,
the Prospectus included therein or any Prospectus Supplement thereto (it being hereby acknowledged and agreed that the written information
set forth on Exhibit C attached hereto is the only written information furnished to the Company by or on behalf of the Investor
expressly for use in any Registration Statement, Prospectus or Prospectus Supplement); and, subject to Section 6(c) and the below provisos
in this Section 6(b), the Investor shall reimburse a Company Party any legal or other expenses reasonably incurred by such Company Party
in connection with investigating or defending any such Claim; provided, however, the indemnity agreement contained in this
Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any
Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld
or delayed; and provided, further that the Investor shall be liable under this Section 6(b) for only that amount of a Claim or
Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the applicable sale of Registrable Securities pursuant
to such Registration Statement, Prospectus or Prospectus Supplement. Such indemnity shall remain in full force and effect regardless of
any investigation made by or on behalf of such Company Party and shall survive the transfer of any of the Registrable Securities by the
Investor pursuant to Section 9.

 

    14

     

    

 

(c) Promptly after receipt by an Investor Party
or Company Party (as the case may be) under this Section 6 of notice of the commencement of any action or proceeding (including, without
limitation, any governmental action or proceeding) involving a Claim, such Investor Party or Company Party (as the case may be) shall,
if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written
notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually
satisfactory to the indemnifying party and the Investor Party or the Company Party (as the case may be); provided, however,
an Investor Party or Company Party (as the case may be) shall have the right to retain its own counsel with the fees and expenses of such
counsel to be paid by the indemnifying party if: (i) the indemnifying party has agreed in writing to pay such fees and expenses; (ii)
the indemnifying party shall have failed promptly to assume the defense of such Claim and to employ counsel reasonably satisfactory to
such Investor Party or Company Party (as the case may be) in any such Claim; or (iii) the named parties to any such Claim (including,
without limitation, any impleaded parties) include both such Investor Party or Company Party (as the case may be) and the indemnifying
party, and such Investor Party or such Company Party (as the case may be) shall have been advised by counsel that a conflict of interest
is likely to exist if the same counsel were to represent such Investor Party or such Company Party and the indemnifying party (in which
case, if such Investor Party or such Company Party (as the case may be) notifies the indemnifying party in writing that it elects to employ
separate counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense
thereof on behalf of the indemnified party and such counsel shall be at the expense of the indemnifying party, provided further
that in the case of clause (iii) above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than
one (1) separate legal counsel for all Investor Parties or Company Parties (as the case may be). The Company Party or Investor Party (as
the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such action
or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Company Party
or Investor Party (as the case may be) which relates to such action or Claim. The indemnifying party shall keep the Company Party or Investor
Party (as the case may be) reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect
thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written
consent; provided, however, the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying
party shall, without the prior written consent of the Company Party or Investor Party (as the case may be), consent to entry of any judgment
or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such Company Party or Investor Party (as the case may be) of a release from all liability in respect to such Claim or litigation,
and such settlement shall not include any admission as to fault on the part of the Company Party. For the avoidance of doubt, the immediately
preceding sentence shall apply to Sections 6(a) and 6(b) hereof. Following indemnification as provided for hereunder, the indemnifying
party shall be subrogated to all rights of the Company Party or Investor Party (as the case may be) with respect to all third parties,
firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the
Investor Party or Company Party (as the case may be) under this Section 6, except to the extent that the indemnifying party is materially
and adversely prejudiced in its ability to defend such action.

 

(d) No Person involved in the sale of Registrable
Securities who is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) in connection with
such sale shall be entitled to indemnification from any Person involved in such sale of Registrable Securities who is not guilty of fraudulent
misrepresentation.

 

(e) The indemnification required by this Section
6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or Indemnified Damages are incurred; provided that any Person receiving any payment pursuant to this Section 6 shall promptly reimburse
the Person making such payment for the amount of such payment to the extent a court of competent jurisdiction determines that such Person
receiving such payment was not entitled to such payment.

 

(f) The indemnity and contribution agreements contained
herein shall be in addition to (i) any cause of action or similar right of the Company Party or Investor Party against the indemnifying
party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

 

    15

     

    

 

ARTICLE
VII

CONTRIBUTIONS

 

7.       Contribution.

 

To the extent any indemnification by an indemnifying
party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for
which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however: (i) no contribution
shall be made under circumstances where the maker would not have been liable for indemnification under the fault standards set forth in
Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) in connection with such sale shall be entitled to contribution from any Person
involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (iii) contribution by any seller
of Registrable Securities shall be limited in amount to the amount of net proceeds received by such seller from the applicable sale of
such Registrable Securities pursuant to such Registration Statement. Notwithstanding the provisions of this Section 7, the Investor shall
not be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by the
Investor from the applicable sale of the Registrable Securities subject to the Claim exceeds the amount of any damages that the Investor
has otherwise been required to pay, or would otherwise be required to pay under Section 6(b), by reason of such untrue or alleged untrue
statement or omission or alleged omission.

 

ARTICLE VIII

REPORTS UNDER THE EXCHANGE ACT

 

8.       Reports
Under the Exchange Act. With a view to making available to the Investor the benefits of Rule 144, the Company agrees to:

 

(a) use its commercially reasonable efforts to
make and keep public information available, as those terms are understood and defined in Rule 144;

 

(b) use its commercially reasonable efforts to
file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act so long as the Company remains subject to such requirements (it being understood that nothing herein shall limit any of the Company’s
obligations under the Purchase Agreement) and the filing of such reports and other documents is required for the applicable provisions
of Rule 144;

 

(c) furnish to the Investor, promptly upon request,
(i) a written statement by the Company, if true, that it has complied with the reporting, submission and posting requirements of Rule
144 and the Exchange Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents
so filed by the Company with the Commission if such reports are not publicly available via EDGAR, and (iii) such other information as
may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and (d) take such
additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to Rule
144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company’s
Transfer Agent without unreasonable delay as may be reasonably requested from time to time by the Investor and otherwise fully cooperate
with Investor and Investor’s broker in their efforts to effect such sale of securities pursuant to Rule 144.

 

    16

     

    

 

ARTICLE
IX

ASSIGNMENT OF REGISTRATION RIGHTS

 

9.       Assignment
of Registration Rights.

 

Neither the Company nor the Investor shall assign
this Agreement or any of their respective rights or obligations hereunder.

 

ARTICLE
X

AMENDMENT OR WAIVER

 

10.       Amendment
or Waiver.

 

No provision of this Agreement may be amended or
waived by the parties from and after the date that is one (1) Trading Day immediately preceding the date of filing of the Initial Registration
Statement with the Commission. Subject to the immediately preceding sentence, no provision of this Agreement may be (i) amended other
than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument signed by the party against
whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or
delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

 

ARTICLE
XI

MISCELLANEOUS

 

11.       Miscellaneous.

 

(a) Solely for purposes of this Agreement, a Person
is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities.
If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities,
the Company shall act upon the basis of instructions, notice or election received from such record owner of such Registrable Securities.

 

    17

     

    

 

(b) Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Agreement shall be given in accordance with Section 10.4 of the Purchase Agreement.

 

(c) Failure of any party to exercise any right
or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.
The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either
party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party
and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other
security being required), this being in addition to any other remedy to which either party may be entitled by law or equity.

 

(d) All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the
exclusive jurisdiction of the federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction,
such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction
or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH
OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(e) The Transaction Documents set forth the entire
agreement and understanding of the parties solely with respect to the subject matter thereof and supersedes all prior and contemporaneous
agreements, negotiations and understandings between the parties, both oral and written, solely with respect to such matters. There are
no promises, undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth in
the Transaction Documents. Notwithstanding anything in this Agreement to the contrary and without implication that the contrary would
otherwise be true, nothing contained in this Agreement shall limit, modify or affect in any manner whatsoever (i) the conditions precedent
to a VWAP Purchase contained in Article VII of the Purchase Agreement or (ii) any of the Company’s obligations under the Purchase
Agreement.

 

    18

     

    

 

(f) This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective successors. This Agreement is not for the benefit of, nor may any provision
hereof be enforced by, any Person, other than the parties hereto, their respective successors and the Persons referred to in Sections
6 and 7 hereof.

 

(g) The headings in this Agreement are for convenience
of reference only and shall not limit or otherwise affect the meaning hereof. Unless the context clearly indicates otherwise, each pronoun
herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,”
 “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without
limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this
entire Agreement instead of just the provision in which they are found.

 

(h) This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have
been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a
 “.pdf” format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com,
www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force and
effect as if the signature were an original signature.

 

(i) Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments
and documents as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby.

 

(j) The language used in this Agreement will be
deemed to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against
any party.

 

[Signature Pages Follow]

 

    19

     

    

 

IN
WITNESS WHEREOF, Investor and the Company have caused their respective signature page to this Registration Rights Agreement
to be duly executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	WEJO Group LIMITED, an exempted company limited by shares incorporated under the laws of Bermuda
	 	 
	 	By:	/s/ John Maxwell 
	 	 	Name: John Maxwell
	 	 	Title: Chief Financial Officer

 

	 	Investors:
	 	 
	 	CF PRINCIPAL INVESTMENTS LLC, a Delaware limited liability company
	 	 	 
	 	By: 	/s/ Mark Kaplan
	 	 	Name: Mark Kaplan
	 	 	Title:

 

     

     

    

 

EXHIBIT A

 

FORM OF NOTICE OF EFFECTIVENESS 

OF REGISTRATION STATEMENT

 

[●]

[●]

[●]

 

Re: Wejo Group Limited

 

Ladies and Gentlemen:

 

We are counsel to Wejo Group Limited, an exempted company limited
by shares incorporated under the laws of Bermuda (the “Company”), and have represented the Company in
connection with that certain Common Stock Purchase Agreement, dated as of February 14, 2022 (the “Purchase
Agreement”), entered into by and among the Company and the Investor named therein (the
 “Holder”) pursuant to which the Company has issued and may issue to the Holder from time to time shares of
the Company’s common stock, par value $0.001 per share (the ”Common Stock”). Pursuant to the
Purchase Agreement, the Company also has entered into a Registration Rights Agreement, dated as of [●], with the Holder (the
 “Registration Rights Agreement”), pursuant to which the Company agreed, among other things, to register
the offer and sale by the Holder of the Registrable Securities (as defined in the Registration Rights Agreement) under the
Securities Act of 1933, as amended (the “Securities Act”). In connection with the Company’s
obligations under the Registration Rights Agreement, on [●], the Company filed a Registration Statement on Form S-1 (File No.
333- [●]) (the “Registration Statement”) with the Securities and Exchange Commission (the
 “Commission”) relating to the resale by the Holder of Registrable Securities and which names the Holder as
an underwriter and a selling stockholder thereunder.

 

In connection with the foregoing, based solely on our review of the
Commission’s EDGAR website, we advise you that the Registration Statement became effective under the Securities Act on [●].
In addition, based solely on our review of the information made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml,
we confirm that the Commission has not issued any stop order suspending the effectiveness of the Registration Statement. To our knowledge,
based solely on our participation in the conferences mentioned above regarding the Registration Statement and our review of the information
made available by the Commission at http://www.sec.gov/litigation/stoporders.shtml, no proceedings for that purpose are pending or have
been instituted or threatened by the Commission.

 

We assume no obligation to update or supplement this letter to reflect
any facts or circumstances which may hereafter come to our attention with respect to the matters herein and statements expressed above,
including any changes in applicable law that may hereafter occur.

 

This letter is being delivered solely for the benefit of the person
to whom it is addressed; accordingly, it may not be quoted, filed with any governmental authority or other regulatory agency or otherwise
circulated or utilized for any purposes without our prior written consent.

 

[Signature Pages Follow]

 

     

     

    

 

	 	Very truly yours,
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

     

     

    

 

EXHIBIT B 

 

SELLING STOCKHOLDER 

 

This prospectus relates to the possible resale from time to time by
CF Principal Investments LLC (“Cantor”) of any or all of the shares of common stock that may be issued by us to Cantor under
the Purchase Agreement. For additional information regarding the issuance of common stock covered by this prospectus, see the section
titled “Cantor Committed Equity Financing” above. We are registering the shares of common stock pursuant to the provisions
of the Registration Rights Agreement we entered into with Cantor on February 14, 2022 in order to permit the selling stockholder to offer the shares
for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement
or as otherwise disclosed in this prospectus, Cantor has not had any material relationship with us within the past three years. As used
in this prospectus, the term “selling stockholder” means Cantor.

 

The table below presents information regarding the selling stockholder
and the shares of common stock that it may offer from time to time under this prospectus. This table is prepared based on information
supplied to us by the selling stockholder, and reflects holdings as of [●] 2022. The number of shares in the column “Maximum
Number of Shares of Common Stock to be Offered Pursuant to this Prospectus” represents all of the shares of common stock that the
selling stockholder may offer under this prospectus. The selling stockholder may sell some, all or none of its shares in this offering.
We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements
or understandings with the selling stockholder regarding the sale of any of the shares.

 

Beneficial ownership is determined in accordance with Rule 13d-3(d)
promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the selling stockholder has voting
and investment power. The percentage of shares of common stock beneficially owned by the selling stockholder prior to the offering shown
in the table below is based on an aggregate of [●] shares of our common stock outstanding on [●]. Because the purchase price
of the shares of common stock issuable under the Purchase Agreement is determined on the VWAP Purchase Date with respect to each VWAP
Purchase, the number of shares that may actually be sold by the Company under the Purchase Agreement may be fewer than the number of shares
being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the selling stockholder pursuant
to this prospectus.

 

     

     

    

 

	 	 	Number of Shares of
 Common Stock 
 Owned Prior to
 Offering	 	Maximum

 Number of

 Shares of

 Common

 Stock 

to be 

Offered

 Pursuant

 to

 this	 	Number of Shares of
 Common Stock
 Owned After Offering	 
	Name of Selling Stockholder	 	Number(1)	 	Percent(2)	 	Prospectus	 	Number(3)	 	 	Percent(2)	 
	CF Principal Investments LLC(4)	 	[●]	 	*	 	[●]	 	 	0	 	 	 	—	 

 

	*	Represents beneficial ownership of less than 1% of the outstanding shares of our common stock. 

 

	(1)	Represents [ ] shares of common stock we issued to CF Principal Investments LLC  as Commitment Shares in consideration for entering into the Purchase Agreement with us.  In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Cantor may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Cantor’s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the VWAP Purchases of common stock are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock to Cantor to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Cantor, would cause Cantor’s beneficial ownership of our common stock to exceed 4.99%.] The Purchase Agreement also prohibits us from issuing or selling shares of our common stock under the Purchase Agreement in excess of the 19.99% Exchange Cap, unless we obtain stockholder approval to do so, or unless sales of common stock are made at a price equal to or greater than $[●] per share, such that the Exchange Cap limitation would not apply under applicable Nasdaq rules. Neither the Beneficial Ownership Limitation nor the Exchange Cap (to the extent applicable under Nasdaq rules) may be amended or waived under the Purchase Agreement.

 

	(2)	Applicable percentage ownership is based on [●] shares of our common stock outstanding as of [●]. 

 

	(3)	Assumes the sale of all shares being offered pursuant to this prospectus. 

 

     

     

    

 

	(4)	The business address of Cantor is 499 Park Avenue, New York, NY 10022. CF Group Management, Inc. (“CFGM”) is the managing general partner of Cantor Fitzgerald, L.P. ("Cantor") and directly or indirectly controls the managing general partner of Cantor Fitzgerald Securities (“CFS”), the sole member of CF Principal Investments, LLC (“CFPI”). Mr. Lutnick is Chairman and Chief Executive of CFGM and trustee of CFGM's sole stockholder. Cantor, indirectly, holds a majority of the ownership interests in CFS, and therefore also indirectly, CFPI. As such, each of Cantor, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of the securities directly held by CFPI. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly. 

 

     

     

    

 

PLAN OF DISTRIBUTION 

 

The shares of common stock offered by this prospectus are being offered
by the selling stockholder, Cantor. The shares may be sold or distributed from time to time by the selling stockholder directly to one
or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of
sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the
shares of our common stock offered by this prospectus could be effected in one or more of the following methods:

 

	 	•	 	ordinary brokers’ transactions;

 

	 	•	 	transactions involving cross or block trades;

 

	 	•	 	through brokers, dealers, or underwriters who may act solely as agents;

 

	 	•	 	“at the market” into an existing market for our common stock;

 

	 	•	 	in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;

 

	 	•	 	in privately negotiated transactions; or

 

	 	•	 	any combination of the foregoing.

 

In
order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for
sale in the state or an exemption from the state’s registration or qualification requirement is available and complied with.

 

Cantor is an “underwriter” within the meaning of Section
2(a)(11) of the Securities Act.

 

Cantor has informed us that it intends to use one or more registered
broker-dealers [(one of which is an affiliate of Cantor)] to effectuate all sales, if any, of our common stock that it may acquire from
us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then
current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities
Act. Cantor has informed us that each such broker-dealer may receive commissions from Cantor and, if so, such commissions will not exceed
customary brokerage commissions.

 

Brokers, dealers, underwriters or agents participating in the distribution
of the shares of our common stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions
from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the selling stockholder through this prospectus.
The compensation paid to any such particular broker-dealer by any such purchasers of shares of our common stock sold by the selling stockholder
may be less than or in excess of customary commissions. Neither we nor the selling stockholder can presently estimate the amount of compensation
that any agent will receive from any purchasers of shares of our common stock sold by the selling stockholder.

 

We know of no existing arrangements between the selling stockholder
or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common stock
offered by this prospectus.

 

     

     

    

 

We may from time to time file with the SEC one or more supplements
to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information
contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a
particular sale of shares offered by this prospectus by the selling stockholder, including the names of any brokers, dealers, underwriters
or agents participating in the distribution of such shares by the selling stockholder, any compensation paid by the selling stockholder
to any such brokers, dealers, underwriters or agents, and any other required information.

 

We will pay the expenses incident to the registration under the Securities
Act of the offer and sale of the shares of our common stock covered by this prospectus by the selling stockholder. As consideration for
its irrevocable commitment to purchase our common stock under the Purchase Agreement, we issued to Cantor [●] shares of our common
stock as Commitment Shares which equals to 3% of Cantor’s total dollar amount purchase commitment under the Purchase Agreement (assuming
a purchase price of $[ ] per share of the Commitment Shares) upon our execution of the Purchase Agreement. In addition, we have agreed
to reimburse Cantor up to $75,000 for the fees and disbursements of counsel in connection with the initial transactions contemplated by
the Purchase Agreement and the Registration Rights Agreement and will reimburse Cantor up to $25,000 each fiscal quarter for the fees
and disbursements of counsel in connection with ongoing bring down diligence procedures.

 

We also have agreed to indemnify Cantor and certain other persons against
certain liabilities in connection with the offering of shares of our common stock offered hereby, including liabilities arising under
the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Cantor
has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us
by Cantor specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect
of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers,
and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed
in the Securities Act and is therefore, unenforceable.

 

We estimate that the total expenses for the offering will be approximately
$[●].

 

Cantor has represented to us that at no time prior to the date of the
Purchase Agreement has Cantor, any of its affiliates or any entity managed or controlled by Cantor engaged in or effected, directly or
indirectly, for its own principal account, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act)
of our common stock or any hedging transaction that establishes a net short position with respect to our common stock. Cantor has agreed
that during the term of the Purchase Agreement, none of Cantor, any of its affiliates nor any entity managed or controlled by Cantor will
enter into or effect, directly or indirectly, any of the foregoing transactions for its own principal account or for the principal account
of any other such entity.

 

We have advised the selling stockholder that it is required to comply
with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder, any affiliated
purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to
induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete.
Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution
of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.

 

This offering will terminate on the date that all shares of our common
stock offered by this prospectus have been sold by the selling stockholder.

 

Our common stock is currently listed on the NASDAQ Global Markets under
the symbol “WEJO”.

 

Cantor and/or one or more of its affiliates has provided, currently
provides and/or from time to time in the future may provide various investment banking and other financial services for us and/or one
or more of our affiliates that are unrelated to the transactions contemplated by the Purchase Agreement and the offering of shares for
resale by Cantor to which this prospectus relates, for which investment banking and other financial services they have received and may
continue to receive customary fees, commissions and other compensation from us, aside from any discounts, fees and other compensation
that Cantor has received and may receive in connection with the transactions contemplated by the Purchase Agreement, including cash fees
for its commitment to purchase shares of our common stock from us under the Purchase Agreement and discounts to current market prices
of our common stock reflected in the purchase prices payable by it for shares of our common stock that we may require it to purchase from
us from time to time under the Purchase Agreement.

 

     

     

    

 

EXHIBIT C

 

BUSINESS ADDRESS & REGULATION SHO

 

The
business address of Cantor is 499 Park Avenue, New York, NY 10022. CF Group Management, Inc. (“CFGM”) is the managing
general partner of Cantor Fitzgerald, L.P. ("Cantor") and directly or indirectly controls the managing general partner of Cantor
Fitzgerald Securities (“CFS”), the sole member of CF Principal Investments, LLC (“CFPI”). Mr. Lutnick is Chairman
and Chief Executive of CFGM and trustee of CFGM's sole stockholder. Cantor, indirectly, holds a majority of the ownership interests in
CFS, and therefore also indirectly, CFPI. As such, each of Cantor, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of
the securities directly held by CFPI. Each such entity or person disclaims any beneficial ownership of the reported shares other than
to the extent of any pecuniary interest they may have therein, directly or indirectly.

 

Cantor
has represented to us that at no time prior to the date of the Purchase Agreement has Cantor or, any of its agents, representatives or
affiliates or any entity managed or controlled by Cantor engaged in or effected, in any manner whatsoever, directly or indirectly, for
its own principal account, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock
or any hedging transaction, which that establishes a net short position with respect to our common stock. Cantor has agreed that during
the term of the Purchase Agreement, neither of Cantor, nor any of its agents, representatives or affiliates nor any entity managed or
controlled by Cantor will enter into or effect, directly or indirectly, any of the foregoing transactions for its own principal account
or for the principal account of any other such entity.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]